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The	main	goal	of	this	project	is	to	study	new	mechanisms	by	which	FSP27	regulates	cell	
physiology	and	to	define	its	putative	role	on	PPAR	signaling	during	fasting.		
	
FSP27	is	a	lipid-droplet	associated	protein	expressed	in	liver	and	white	and	brown	
adipose	tissues,	which	promotes	intracellular	lipid	accumulation	and	prevents	lipolysis	
(Puri	2013).		
	
There	are	two	different	isoforms	of	FSP27	that	encode	for	two	different	proteins,	the	
FSP27α	that	is	mainly	expressed	in	white	adipose	tissue	and	FSP27β,	the	unique	form	
expressed	in	liver	and	also	expressed	in	brown	adipose	tissue.	The	alternative	β	
isoform	contains	10	additional	amino	acids	at	the	N	terminus	of	the	original	FSP27α	
(Xu	et	al.	2015).		
	
The	expression	of	Fsp27β	is	induced	by	the	cyclic-AMP-responsive	element-binding	
protein	H	(CREBH),	a	transcription	factor	that	regulates	lipid	and	glucose	metabolism	
(Xu	et	al.	2015).	Previous	work	developed	in	our	lab	identified	Fsp27	as	a	key	gene	up	
regulated	in	the	liver	on	the	early	response	to	fasting.	Fsp27	is	induced	in	an	early	
fasting	(6-15h),	but	not	during	longer	periods	of	starvation,	suggesting	that	Fsp27	is	
specifically	responsive	to	the	signals	of	an	early	response	to	fasting.	(Vilà-Brau	et	al.	
2013)		
	
It	is	known	that	the	“new	fat”,	fat	that	comes	from	diet	or	from	de	novo	synthesis	via	
fatty	acid	synthase	(FASN)	is	capable	of	activating	PPARα,	but	the	“old	fat”,	the	fat	
stored	in	the	adipocytes,	cannot.	This	leads	to	an	important	paradox,	since	
PPARα target	genes	are	expressed	in	fasting	situations,	but	PPARα itself	should	not	be	
active	(Chakravarthy	et	al.	2005).	The	activation	of	PPARα	target	genes	is	impaired	
when	the	FASN	is	not	active	or	absent	(in	a	knockout	mice),	and	that	led	to	the	
discovery	of	1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine	(16:0/18:1	PC)	as	a	
ligand	for	PPARα	(Chakravarthy	et	al.	2010).	Another	phosphocholine	species,	the	
18:0/18:1	PC,	was	described	as	being	a	serum	lipid	regulated	by	diurnal	hepatic	
PPARα activity	(Liu	et	al.	2013).	
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	All	together	uncovers	a	link	between	Fsp27	expression	pattern	and	its	role	in	the	
unilocular	lipid	droplet	formation,	and	the	availability	of	PPARα	ligands	coming	from	
the	new	fat,	in	fasting	and	feeding	situations.	In	this	context	the	hypothesis	of	this	
Thesis	is	that	the	activity	of	FSP27	could	promote	the	intrahepatic	accumulation	of	
newly	synthesized	phospholipids	during	the	early	fasting	state,	which	would	then	be	
released	into	circulation,	thus	regulating	the	availability	of	endogenous	ligands	of	
PPARα. 	
	
The	work	developed	in	this	Thesis	was	divided	into	three	different	chapters,	the	
regulation	of	Fsp27	during	the	fasting	adaptation,	the	transcriptional	regulation	of	
Fsp27	in	liver	and	finally	the	role	of	FSP27	as	a	lipid-droplet	protein	in	PPARα	signaling,	
with	the	purpose	to	understand	the	following	objectives:	
	
1) To	 describe	 the	 expression	 pattern	 of	 FSP27	 during	 fasting	 adaptation	 in	
different	tissues	and	different	fasting	times.		
2) To	define	the	transcriptional	mechanisms	responsible	for	hepatic	expression	of	
FSP27	during	fasting	specially	the	ones	that	cause	the	fall	of	Fsp27β	expression	
during	late	fasting.		
3) To	 identify	 the	 role	 of	 Fsp27β	 in	 PPARα	 signaling	 by	 studying	 its	 ability	 to	
control	 the	 store/release	 of	 specific	 endogenous	 ligands	 of	 PPARa	 from	 lipid	
droplets.					
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1. Liver	Fatty	Acid	Metabolism	
	
	
Deregulation	 of	 lipid	 metabolism	 lies	 at	 the	 base	 of	 the	 most	 common	 medical	
disorders	 in	 western	 populations,	 such	 as	 cardiovascular	 disease,	 obesity,	 diabetes,	
and	 fatty	 liver	 conditions.	However,	 a	 gap	of	 knowledge	 still	 exists	 in	both	 the	basic	
science	and	the	clinical	 fields	regarding	the	 impact	of	altered	 lipid	storage	on	human	
disease.	
The	liver	can	both	oxidize	and	synthetize	fatty	acids.	In	humans	the	overall	rate	of	fatty	
acid	 synthesis	 from	 other	 molecules	 (glucose	 in	 particular)	 is	 usually	 small	 in	
comparison	 with	 dietary	 fatty	 acid	 intake,	 nonetheless	 this	 pathway	 has	 a	 special	
significance	in	coordinating	glucose	and	fat	metabolism,	and	in	generating	the	ligands	
for	the	appropriated	PPARa	activation,	as	discussed	below.		
	
	
1.1 Fatty	acid	oxidation	in	liver	during	adaptation	to	fasting		
	
	
The	hepatic	fatty	acid	oxidation	(FAO)	plays	a	central	role	in	the	adaptive	response	to	
fasting.	 The	plasma	hormone	profile	 in	 this	 situation,	 low	 insulin	 and	high	 glucagon,	
induces	the	release	of	large	amounts	of	fatty	acids	from	the	adipose	tissue	to	be	used	
by	peripheral	tissues	and	spare	glucose	consumption.	Therefore,	the	liver	of	a	starved	
animal	 actively	 oxidizes	 fatty	 acid,	 which	 provides	 the	 energy	 necessary	 to	 sustain	
gluconeogenesis.	 It	 also	 supplies	 the	 acetyl-CoA	 needed	 for	 active	 ketone	 body	
synthesis,	 which	 replaces	 glucose	 as	 the	 energy	 substrate	 for	 the	 brain	 and	 other	
tissues	(McGarry	and	Foster	1995).		
Two	 enzymes	 determine	 the	 metabolic	 fate	 of	 fatty	 acids	 in	 the	 liver	 of	 starved	
animals:	 carnitine	 palmitoyltransferase-1	 (CPT1)	 A	 and	 hydroxymethylglutaryl	 CoA	
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synthase	2	 (HMGCS2).	Cpt1A	 encodes	a	malonyl-CoA-sensitive	protein	 that	 regulates	
mitochondrial	 long	 chain	 fatty	 acid	 oxidation	 (McGarry	 and	 Foster	 1995),	 whereas	
Hmgcs2	encodes	a	mitochondrial	protein	that	controls	the	3-hydroxy-3-methylglutaryl-
CoA	 (HMG-CoA)	 cycle,	 by	 which	 acetoacetate,	 b-hydroxybutyrate,	 and	 NAD+	 are	
generated	 (Hegardt	1995).	 The	expression	of	both	genes	 is	 regulated	by	peroxisome	
proliferator-activated	receptor	α	(PPARα)	(Napal,	Marrero,	and	Haro	2005;	Ortiz	et	al.	
1999;	Rodríguez	et	al.	1994;	Hsu	et	al.	2001),	 a	 fatty	acid-activated	nuclear	 receptor	
that	 regulates	metabolic	 changes	 in	 the	 liver	 associated	with	 starvation	 (see	below).	
Consistently,	 during	 starvation,	 PPARα	 null	 mice	 show	 severe	 hypoglycemia	 and	
hypoketonemia	 (Kersten	et	al.	1999).	The	hypoglycemia	 is	due	to	a	 reduced	capacity	
for	hepatic	gluconeogenesis	secondary	to	a	70%	lower	rate	of	fatty	acid	oxidation.	The	
liver	Hmgcs2	expression	during	fasting	 is	 relevant	to	produce	ketone	bodies	that	will	
avoid	glucose	utilization,	but	also	to	maintain	an	active	FAO	(Figure	I1).	Thus,	knocking	
down	Hmgcs2	expression	impairs	fatty	acid	oxidation	(Vilà-Brau	et	al.	2011a).		
	
	
Figure	 I1.	 Role	 of	 liver	 FAO	 in	 generating	 the	 energy	 and	 reduction	 power	 needed	 to	 produce	 glucose	 during	
fasting.	 Energy	 is	 obtained	 from	 FAO	 to	 perform	 gluconeogenesis	 from	 precursors	 (lactate,	 glycerol	 or	 alanine).	
Complete	oxidation	of	FA	is	compromised	by	the	gluconeogenic	use	of	oxaloacetate.	Ketone	body	production	allows	
the	 incomplete	b-oxidation	 and	 liberates	 the	 Ac-CoA	molecule	 needed	 for	 fatty	 acid	 activation.	 Gluconeogenesis	
produces	 NAD+,	 an	 essential,	 and	 consumed,	 substrate	 for	 Sirt1	 activity.	 Adapted	 from	 Foster	 and	 	 McGarry		
(McGarry	and	Foster	1995)	and	Vilá	Brau	et	al.(Vilà-Brau	et	al.	2011a;	Vilà-Brau	et	al.	2013).		
	
	
In	addition	 to	 this	network	of	genes	 regulated	by	PPARα	activation,	another	enzyme	
may	 contribute	 to	 the	metabolic	 adaptation	 to	 fasting:	 SirT1	 (sirtuin	 1).	 This	 NAD+-
dependent	 protein	 deacetylase	 is	 a	 general	 regulator	 of	 energy	 homeostasis	 in	
response	 to	 nutrient	 availability	 (Nemoto,	 Fergusson,	 and	 Finkel	 2004).	 Thus,	 the	
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adaptation	 program	 to	 fasting	 in	 liver	 can	 be	 divide	 into	 two	 temporally	 distinct	
phases:	 the	 onset	 of	 fasting	 (<12–18	 h)	 and	 sustained	 fasting	 (>12–18	 h)	 that	 are	
distinguishable	 by	 the	 NAD+	 mediated	 SirT1	 activation	 (Dominy	 et	 al.	 2010).	 The	
activation	 of	 SIRT1	 results	 in	 the	 deacetylation	 of	 transcription	 factors	 and	 co-
activators	providing	a	mechanism	to	further	amplify	gluconeogenic	gene	expression	in	
response	to	prolonged	fasting	(Altarejos	and	Montminy	2011).		
	
	
1.2 Hepatic	SIRT1	activity	in	long	Fasting	and	its	target	genes		
	
	
At	the	onset	of	fasting,	circulating	levels	of	glucose	fall,	there	is	an	increase	the	levels	
of	 glucagon	 and	 a	 decrease	 in	 insulin.	 In	 the	 first	 phase	 of	 fasting	 (<12h-18h)	
gluconeogenesis	is	upregulated	in	liver.	The	transcription	of	gluconeogenic	enzymes	is	
initiated	 by	 activation	 of	 cAMP	 response	 element	 binding	 protein	 (CREB)	 and	 its	
coactivator	 CRTC2.	 However,	 in	 longer	 periods	 of	 fasting	 (>12-18h)	 CRTC2	 protein	
degradation	 is	 signaled	 by	 SIRT1	 deacetylation	 (Lay	 et	 al.	 2010).	 Therefore,	 the	
maintenance	of	the	gluconeogenic	response	in	prolonged	fasting	will	be	mediated	by	
PGC1-α and	 its	 related	 transcription	 factors	 (Figure	 I2).	 An	 increase	 in	 PGC1α	 levels	
facilitates	 increased	 hepatic	 glucose	 output	 by	 promoting	 the	 expression	 of	
gluconeogenic	genes	such	as	Pepck	and	G6Pase(Dominy	et	al.	2010).		
	
In	addition	to	co-activators,	SIRT1	mediated	deacetylation	can	modulate	the	activity	of	
several	 transcription	 factor.	 Thus,	 SIRT1	 may	 support	 residual	 expression	 of	 the	
gluconeogenic	program	during	late	fasting	by	deacetylation	and	enhancing	the	activity	
of	 the	 forkhead	 activator	 FOXO1	 (Y.	 Liu	 et	 al.	 2009).	 Importantly,	 activation	 of	
PGC1α and	FOXO1	also	stimulate	fatty	acid	oxidation	(Napal,	Marrero,	and	Haro	2005)	
and	ketogenesis(Nadal,	Marrero,	and	Haro	2002),	when	insulin	is	absent,	respectively.		
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Figure	 I2.	 A	 proposed	 theory	 for	 the	 temporal	 regulation	 of	 two	 major	 transcriptional	 coactivators	 involved	 in	
hepatic	 gluconeogenesis	 during	 fasting.	 CRTC2	 deacetylation	 facilitates	 ubiquitination	 and	 degradation.	 PGC1a	
deacetylation	 increases	protein	stability.	Deacetylation	of	FOXO1	and	CREBH	stimulates	and	reduces,	 respectively	
their	transcriptional	activity.		
	
	
	
1.3 Role	of	CREBH	acetylation	during	fasting	adaptation		
	
CREBH	 (CREBH:	 cyclic-AMP-responsive	element	binding	protein	H)	 is	 an	 Endoplasmic	
Reticulum	 transcription	 factor,	 which	 possesses	 similarity	 to	 SREBP	 as	 regards	 its	
localization	and	the	activation	process	of	its	cleavage	system.	CREBH	is	involved	in	the	
regulation	 of	 several	 metabolic	 pathways,	 such	 as	 lipogenesis,	 FA	 and	 cholesterol	
metabolism	and	lipolysis,	under	metabolic	stress	conditions	in	order	to	maintain	lipid	
homeostasis	(C.	Zhang	et	al.	2012).		
	
During	 fasting	CREBH	expression	 is	 induced	by	the	glucocorticoid	receptor	 (GR)/PGC-
1α	complex,	and	the	HNF4α/PGC1α	complex	(M.	W.	Lee	et	al.	2010).	The	mature	form	
of	CREBH	up-regulates	gluconeogenic	genes	such	Pepck	and	G6Pase	(M.	W.	Lee	et	al.	
2010)	in	the	livers	of	mice	in	fasted	state	via	directly	binding	to	CRE	(cAMP	responsive	
element).	 CREBH	 also	 stimulates	 FAO	 and	 ketogenesis	 in	 the	 liver	 of	 fasted	 animals	
throughout	an	indirect	mechanism	that	involves	FGF21,	a	unique	member	of	the	FGF	
family	 with	 hormone-like	 actions(Kharitonenkov,	 A.	 Shiyanova	 et	 al.	 2005).	 CREBH	
directly	 binds	 to	 the	 proximal	 region	 of	 the	 Fgf21	 promoter	 and	 upregulates	 its	
expression	 (H.	 Kim	et	 al.	 2014).	 FGF21	 is	 a	 key	mediator	of	 starvation	 that	 activates	
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lipolysis	 in	 white	 adipose	 tissue	 (WAT)	 and	 increases	 fatty	 acid	 oxidation	 and	
ketogenesis	in	the	liver	(Kharitonenkov,	A.	Shiyanova	et	al.	2005).		
Fgf21	is	also	a	bona	fide	PPARα	target	gene	(Badman	et	al.	2007;	Inagaki	et	al.	2007),	
although	 the	 presence	 of	 CREBH	 is	 needed	 for	 the	 PPARa-mediated	 Fgf21	 induction	
during	 fasting	 (Danno	et	al.	2010).	 In	addition,	CREBH	 is	acetylated	 in	 the	 liver	upon	
fasting	 in	 a	 time-dependent	 manner	 and	 this	 acetylation	 is	 crucial	 to	 maintain	 the	
hepatic	 lipid	homeostasis	 in	a	 fasting	 state	 (Hyunbae	Kim	et	al.	 2015a).	 Therefore,	 a	
cooperative	 model	 (Figure	 I3)	 between	 CREBH	 and	 PPARα	 has	 been	 proposed	 to	
explain	 upregulation	 of	 Fgf21	 expression	 by	 both	 CREBH	 and	 PPARα	 (Danno	 et	 al.	
2010;	Hyunbae	Kim	et	al.	2015a).	In	this	model,	upon	states	of	fasting,	cleavage	of	the	
CREBH	 protein	 occurs	 (see	 below).	 The	 cleaved	 activated	 form	 of	 CREBH	 will	 be	
released	 and	 moved	 to	 the	 nucleus,	 where	 the	 histone	 acetyltransferase	 PCAF	
mediates	 the	 acetylation	 of	 CREBH	 at	 K294.	At	 the	 same	 time,	 SIRT1	modulates	 the	
acetylation	 phenomenon	 through	 its	 deacetylation	 activity	 (Figure	 I3).	 Globally,	 this	
acetylation	 process	 is	 essential	 for	 the	 interaction	 between	 CREBH	 and	 PPARa,	 and	
therefore	for	the	activation	of	its	target	genes	in	fasting	(Hyunbae	Kim	et	al.	2015a).	
	
	
Figure	I3.	Model	for	the	regulation	of	CREBH	activity	by	acetylation	in	fasted	states.	Cooperative	action	of	PPARa	
and	nuclear	 form	of	 CREBH	on	 genes	 like	Fgf21.	 CREBH	 is	 stimulated	 by	 PCAF-dependent	 acetylation	 (Kim	et	 al.	
2015).	
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NEFAs	 arriving	 from	 WAT	 are	 involved	 in	 the	 CREBH	 nuclear	 protein	 accumulation	
under	fasting	by	promoting	CREBH	cleavage.	Hence,	in	the	fasted	state,	the	expression	
of	CREBH	mRNA	and	nuclear	protein	are	both	suppressed	by	refeeding	in	the	wild-type	
mice,	 but	not	 in	 the	ob/ob	mice	 (Danno	et	 al.	 2010).	 Interestingly,	 animals	 in	which	
WAT	 lipolysis	 has	 been	 ablated	 (CGI-58-ATko),	 and	 there	 is	 not	 a	 FA	 supply	 upon	
fasting,	 shown	 a	 marked	 defect	 in	 liver	 PPARa-signaling	 and	 nuclear	 CREBH	
translocation	 (Jaeger	 et	 al.	 2015).	 Therefore,	 CREBH	 cleavage	 in	 the	 ER	 could	 be	
relevant	 to	 signaling	 the	 presence	 of	 this	 old	 fat	 (see	 below)	 in	 liver	 throughout	
PPARα-mediated	FGF21	activation	(Figure	I4)	
	
Figure	 I4.	 Proposed	 moldel	 for	 FA	 stimulation	 of	 CREBH	 translocation	 to	 nucleus.	 CGI-58,	 Comparative	 gene	
identification-58	 (ATGL	 co-activactor);	 G0S2,	 G0/G1	 Switch	 Gene	 2	 (ATGL	 inhibitor);	 ATGL,	 Adipose	 triglyceride	
lipase;	 AOX;	 Acyl-CoA	 oxidase;	 MCAD,	 Medium-chain	 acyl-CoA	 dehidrogenase;	 LCAD,	 Long-chain	 acyl-CoA	
deshidrogenase;	 	 ER,	 endoplasmic	 reticulum.	 AOX,	MCAD,	 and	 LCAD	 are	 PPARa	 target	 genes.	 From	 Jaeger	et	 al.	
2015.		
	
	
	
2. Peroxisome	Proliferator	Activated	Receptors	(PPARs)	as	
Regulators	of	Fat	Metabolism		
	
	
The	 PPARs	 belong	 to	 the	 ligand-activated	 nuclear	 receptor	 family	 and	 the	 steroid	
receptor	superfamily.	The	nuclear	receptors	(NR)	are	a	family	of	transcription	factors	
that	can	exert	their	effects	as	monomers,	homodimers	or	heterodimers	by	binding	to	
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specific	sequences	of	DNA	called	Nuclear	Receptors	Responsive	Elements	(NRRE)	with	
a	 repetitive	 consensus	 hexamer	 (AGGTCA)	 that	 is	 recognized	 by	 the	 DNA	 binding	
domain	 (DBD)	 of	 the	NR.	 All	 of	 the	NRs	 share	 a	 common	 structure,	 a	NH2	 terminal	
region	(A/B),	a	conserved	DBD	(region	C)	that	includes	two	ZN	fingers,	a	linker	region	
(D)	responsible	for	nuclear	 localization,	and	finally	a	well	conserved	carboxy-terminal	
ligand-binding	domain,	 the	LBD,	or	region	E.	Some	of	the	NR	may	possess	an	extra	F	
domain,	with	unknown	functions	so	far,	a	highly	variable	carboxy-terminal	tail	(Feige	et	
al.,	n.d.;	Sever	and	Glass	2013).		
PPARs	regulate	the	expression	of	genes	involved	in	a	variety	of	processes,	concerning	
the	 metabolic	 homeostasis	 by	 controlling	 the	 metabolism	 of	 glucose	 and	 lipids,	
(Monsalve	et	al.	2013).	For	the	PPAR-mediated	transcriptional	activation	of	 its	 target	
genes	 it	 is	necessary	 the	heterodimerization	of	a	PPAR	with	RXR,	and	 the	binding	of	
the	 heterodimer	 to	 a	 PPRE	 sequence,	 producing	 a	 change	 in	 chromatin	 structure	
indicated	by	 ligand	activation	of	 the	complex	and	histone	H1	release.	The	binding	of	
the	 ligand	 triggers	 a	 conformational	 change	 that	will	 generate	 new	 specific	 contacts	
with	 coactivators	 (Desvergne,	Michalik,	 and	Wahli	 2006).	 Like	 PPARs	 are	 controlling	
lipid	homeostasis	(lipid	synthesis	and	oxidation)	and	are	activated	by	lipids	(or	a	closely	
related	derivate)	that	are	acting	as	ligands	(see	below),	necessarily	the	mechanism	of	
activation	by	lipids	may	be	far	baroque	than	the	description	presented	here.		
	
2.1 PPAR	isotypes	and	metabolic	integration		
	
	
Despite	their	different	tissue	distribution,	this	subfamily	of	nuclear	receptors	function	
in	an	integrated	network	to	regulate	metabolism	(Evans	2004).	The	PPARs	function	as	
lipid	 sensors,	 in	 a	 way	 that	 can	 be	 activated	 by	 both	 dietary	 fatty	 acids	 and	 their	
derivatives	in	the	body	and	consequently	redirect	metabolism.	
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The	 alpha	 isoform	 of	 the	 PPARs	 (PPARα)	 has	 a	 crucial	 role	 in	 FAO	 and	 therefore	 is	
found	mainly	in	highly	oxidative	tissues,	its	mRNA	is	expressed	in	liver,	and	at	a	lesser	
extent	in	heart,	kidneys,	skeletal	muscle	and	BAT.	PPARa	is	shown	to	have	a	crucial	role	
in	 the	 adaptive	 response	 to	 fasting	 by	 regulating	 genes	 involved	 in	 FAO	 (Napal,	
Marrero,	and	Haro	2005;	Rodríguez	et	al.	1994),	therefore	having	consequent	indirect	
effects	 on	 other	 metabolic	 pathways	 and	 energy	 homeostasis(Kersten	 et	 al.	 1999;	
Desvergne,	Michalik,	and	Wahli	2006;	Evans	2004).	
	
PPARψ	 is	 highly	 enriched	 in	 both	 BAT	 and	 WAT.	 It	 is	 induced	 during	 adipocyte	
differentiation	and	 it	 is	 thought	 to	be	an	 important	 regulator	of	 fat	 cells(Lazar	2002;	
Tsai,	 Y.S.,	 and	 Maeda	 2005).	 This	 member	 of	 the	 PPARs	 is	 a	 master	 effector	 of	
adipogenesis	 in	a	transcriptional	cascade	 involving	C/EBP	(Z.	Wu	et	al.	1999)	and	has	
an	important	role	in	the	regulation	of	glucose	and	lipid	metabolism.	It	also	participates	
in	 the	 regulation	 of	 cardiovascular	 disease,	 inflammation,	 organ	 development	 and	
tumor	formation	(J.	H.	Kim,	Song,	and	Park	2015).		According	to	its	functions,	PPARψ-
adipose	KO	mice	are	protected	from	HFD-induced	obesity	and	insulin	resistance(Jones	
et	al.	2005)	and	in	humans,	a	dominant	negative	mutation	in	a	single	allele	of	PPARG	
(encoding	for	PPARψ)	leads	to	insulin	resistance	and	lipodystrophy	phenotype.	Finally,	
this	transcription	factor	is	of	great	clinical	importance,	since	it	is	the	molecular	target	
for	the	thiazolidinedione	(TZD).	TZDs	are	a	class	of	antidiabetic	agents,	which	improve	
peripheral	 insulin	sensitivity	and	assist	 in	glycemic	control	 in	 type	2	diabetic	patients	
(Lehmann	et	al.	1995).	
	
The	third	member	of	this	family,	PPARδ,	has	been	the	more	elusive	one.	It	expression	
is	quite	ubiquitous	and	originally	its	functions	were	center	on	fatty	acid	catabolism	and	
energy	homeostasis	(Evans	2004).		It	is	considered	an	important	metabolic	regulator	in	
different	tissues,	such	as	adipose	tissue,	skeletal	muscle	and	heart	(Barish,	Narkar,	and	
Evans	2006).	
	
The	 transcriptional	 activation	 of	 PPARδ	 enhances	 fatty	 acid	 catabolism	 and	 energy	
uncoupling,	 decreasing	 TG	 stores,	 improving	 endurance	 performance	 and	 enhancing	
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cardiac	 contractility.	 Its	 receptor	 activation	 decreases	 macrophage	 inflammatory	
responses	and	modulates	lipoprotein	metabolism	to	lower	TG	and	on	the	other	hand,	
to	raise	HDL	cholesterol.	In	liver,	the	activation	of	this	transcription	factor	ameliorates	
glucose	homeostasis,	by	repressing	hepatic	glucose	output	(Barish,	Narkar,	and	Evans	
2006).		
In	muscle	 it	 is	 attributed	a	 fundamental	 role	 in	 the	 regulation	of	mitochondrial	 fatty	
acid	 oxidation.	 Thus,	 overexpression	 of	 PPARδ	 in	 muscle	 increases	 the	 oxidative	
capacity	 in	a	very	marked	way.	 In	 fact,	mice	 that	express	 large	amounts	of	PPARd	 in	
muscle	(marathon	mice)	can	run	for	hours	without	stopping	(Y.	X.	Wang	et	al.	2004)(Y.	
X.	Wang	et	al.	2004).		
	
However,	 in	 liver,	 PPARδ	 plays	 a	 lipogenic	 role	 as	 indicated	 by	 overexpression	
(adenovirus)	experiments(S.	Liu	et	al.	2011)	or	knockout	animal	models(Barish,	Narkar,	
and	Evans	2006).	Recently,	 it	has	been	shown	that	PPARδ	controls	diurnal	expression	
of	lipogenic	genes	in	the	dark/feeding	cycle	(S.	Liu	et	al.	2013).	Surprising,	liver-specific	
PPARδ activation	increases,	whereas	hepatocyte	PPARδ	deletion	reduces,	muscle	fatty	
acid	uptake(S.	Liu	et	al.	2013)	(see	below).		
	
	
2.2 New	Fat	are	the	PPARα 	endogenous	ligands		
	
	
As	mentioned,	PPARα-null	mice	develop	a	phenotype	characterized	by	hypoglycemia,	
hyperlipidemia,	hypoketonemia,	and	fatty	liver	due	to	its	inability	to	meet	the	energy	
demands	in	a	fasting	state	(Kersten	et	al.	1999).	The	FASKOL	mice	lack	the	capacity	of	
synthetizing	 fatty	 acid	 from	 carbohydrate,	 by	 the	 deletion	 of	 fatty	 acid	 synthase	
(FASN).	 This	 animal	 when	 either	 fed	 with	 a	 fat	 free	 diet	 or	 exposed	 to	 prolonged	
fasting	 showed	 the	 same	 hypoglycemic	 phenotype	 than	 PPARα-null	 mice,	 with	
decreased	 expression	 of	 PPARα	 target	 genes.	 FASKOL	 mice	 also	 developed	 a	
cholesterol	phenotype,	not	dependent	on	diet.	Both	the	hypoglycemia/steatohepatitis	
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and	the	cholesterol	phenotypes	were	reversed	by	administration	of	a	PPARα	agonist	
such	as	WY14643	(Chakravarthy	et	al.	2005).	Since	the	“new	fat”	is	the	fat	that	comes	
from	diet	or	from	de	novo	synthesis	via	FASN,	this	experiment	led	to	the	concept	that	
only	“new	fat”	is	capable	of	activating	PPARa	and	promoting	gluconeogenesis	and	FAO.	
By	contrast,	the	“old	fat”,	the	fat	mobilized	from	peripheral	fat	stores	and	transported	
to	the	liver	where	it	accumulates,	fails	to	activate	PPARα	(see	Figure	I5).		
Later,	 by	 immunoprecipitation	 of	 PPARα,	 an	 endogenous	 ligand	 with	 nanomolar	
affinity	was	described	for	PPARa	activation:	that	the	1-palmitoyl-2-oleoyl-sn-glycerol-3-
phosphocholine	(16:0/18:1	PC)	(Chakravarthy	et	al.	2010).	
	
Figure	 I5.	“Proposed	model	 for	differential	effects	of	hepatic	 lipid.	Fat	absorbed	from	the	diet	or	synthesized	de	
novo	 via	 FAS	 in	 the	 liver	 constitutes	 “new”	 fat,	 capable	 of	 activating	 PPARα	 to	 ensure	 normal	 glucose	 and	 lipid	
homeostasis.	 Fat	 derived	 from	 peripheral	 mobilization	 of	 adipose	 stores	 constitutes	 a	 different	 hepatic	
compartment	(“old”	fat)	that	does	not	appear	to	activate	PPARα	as	effectively	as	new	fat,	leading	to	fatty	liver.	In	
contrast	 to	 de	 novo	 synthesized	 fat,	 dietary	 fat	 is	 inadequate	 for	 the	 maintenance	 of	 cholesterol	 homeostasis,	
suggesting	different	PPARα	pools”	(Chakravarthy	et	al.	2005).		
	
Hence,	PPARα	 is	activated	by	specific	fatty-acid	pools	synthesized	by	hepatic	FASN	or	
derived	from	diet,	but	not	from	peripheral	FA	and	this	leads	to	an	important	paradox,	
since	PPARα	target	genes	are	expressed	in	fasting	situations,	when	PPARα	itself	should	
not	be	active	(see	Discussion	Section).	
	
	
2.3 PPARδ 	can	generate	the	PPARa	endogenous	ligands		
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PPARδ	 overexpression	 (adenoviral-mediated	 PPARδ)	 up-regulates	 glucose	 utilization	
and	de	novo	 lipogenesis	pathways	 (S.	Liu	et	al.	2011).	Liver-specific	PPARδ	activation	
increases,	whereas	 hepatocyte-PPARδ	 deletion	 reduces,	muscle	 fatty	 acid	 uptake	 (S.	
Liu	 et	 al.	 2013).	 Therefore,	 apparently	 a	 PPARd	 dependent	 signal	 couples	 liver	 lipid	
metabolism	to	muscle	FAO	(S.	Liu	et	al.	2013).		
	
Profiling	of	lipid	metabolites	of	samples	from	wild	type	and	LPPARDKO	mice	revealed	
that	 the	 main	 differences	 in	 serum	 occurred	 during	 the	 dark	 cycle,	 when	
PPARδ controlled	 lipogenesis	 is	 active.	 Nonetheless,	 daytime	 feeding	 led	 to	 serious	
differences	 in	 serum	 lipidomes	 of	 the	 two	 genotypes,	 showing	 that	 LPARDKO	 mice	
were	unable	to	adjust	their	lipogenic	gene	expression	program.	
	
Acetyl-CoA	carboxylase	(Acc1),	rate-limiting	enzyme	in	de	novo	lipogenesis,	is	induced	
by	 PPARd	 overexpression	 (adPPARδ).	 While	 transitory	 Acc1	 knockdown	 (LACC1KD)	
mice	 shows:	 i)	 reduced	 hepatic	 TAG,	 ii)	 increased	 serum	 TAG,	 and	 iii)	 decrease	 FFA	
uptake	in	isolated	soleus	muscle.	Muscle	FA	uptake	decreased	in	LACC1KD	mice	in	the	
dark/feeding	cycle,	when	the	lipogenic	program	is	active	and	additionally	there	was	a	
slower	 clearance	of	 circulating	 [3H]	oleic	 acid.	 Thus,	de	novo	 lipogenesis	 is	 linked	 to	
muscle	FA	use(S.	Liu	et	al.	2013).	
	
Unbiased	 metabolite	 profiling	 identifies	 1-stearoyl-2-oleoyl-sn-glycero-3-
phosphocholine	 (PC	 18:1/18:0)	 as	 a	 serum	 lipid	 regulated	 by	 diurnal	 hepatic	 PPARδ	
activity.	 PC	 (18:0/18:1)	 reduces	 postprandial	 lipid	 levels	 and	 increases	 fatty	 acid	 use	
through	muscle	PPARα.	Put	together,	this	links	the	hepatic	PPARδ-controlled	lipogenic	
program	to	serum	lipid	concentrations	and	muscle	fat	use.		
	
PPARδ expression	peaks	 at	 night,	 parallel	 to	 the	mRNA	 levels	 of	 the	molecular	 clock	
Bmal1	in	the	liver.	Therefore,	 it	 is	feasible	that	hepatic	PPARδ	alter	the	expression	of	
muscle	genes	and	FA	use	through	PC	 (18:0/18:1),	 indicating	that	a	hepatic	PPARδ-PC	
(18:0/18:1)-muscle	 PPARα signaling	 cascade	 coordinates	 fat	 synthesis	 and	 use.	 That	
PPARα	 ligands	are	products	of	 the	de	novo	synthesis	of	FA	 illustrates	a	 link	between	
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hepatic	 lipogenesis	and	peripheral	FAO.	This	 link	can	explain	how	tissues	 like	muscle	
oxidize	 fatty	 acids,	 depending	 on	 circadian	 hepatic	 synthesis,	 at	 specific	 times	
coinciding	to	the	animal	activity.		
	
	
	
3. Fat-Specific	protein	FSP27/CIDEC		
	
	
The	 production	 of	 endogenous	 ligand	 of	 PPARa	 requires	 an	 esterification	 and	 re-
hydrolysis	cycle	 (Ong	et	al.	2011),	 suggesting	 that	 lipid	droplet	 (LD)	 formation	during	
the	fed-to-fasting	transition	could	be	necessary	for	PPARSYMBOL	
	activation.	 In	 vivo	 attenuation	 of	 liver	 ketogenesis	 (siRNA)	 downregulate	 FAO	 and	
Fgf21	expression	(Vilà-Brau	et	al.	2011a).	 In	this	model,	mRNA	analysis	 indicates	that	
Fsp27	 is	 one	 of	 the	 genes	 induced	 by	 liver	 knock	 down	 of	Hmgcs2	 (Vilà-Brau	 et	 al.	
2013).	Fsp27	 (CIDEC	 in	humans)	 is	a	 lipid	droplet	 (LD)	 formation	protein	and	call	our	
attention	since	was	induce	during	starvation	in	liver(Vilà-Brau	et	al.	2013).	
	
The	CIDE	family	of	proteins	comprises	three	distinct	isotypes;	CIDEA,	CIDEB	and	CIDEC	
(FSP27	 in	 mice)	 that	 were	 first	 identified	 by	 their	 sequence	 homology	 with	 the	 N	
terminal	 domain	 of	 the	 DNA	 fragmentation	 factor	 (DFF)	 and	 described	 as	 apoptosis	
activators.	 When	 transfected	 in	 adherent	 cells,	 they	 induce	 morphological	 changes,	
nuclear	condensation	and	fragmentation,	key	characteristics	of	apoptosis	 (Inohara	et	
al.	 1998).	 	 The	 CIDE	 proteins	 are	 essentially	 lipid	 droplet-associated	 proteins	 and	
important	regulators	of	lipid	storage	and	formation	of	lipid	droplets	in	adipocytes	and	
hepatocytes	but	their	roles	seem	to	be	more	complex	and	intricate	in	the	regulation	of	
lipid	 metabolism	 and	 be	 crucially	 involved	 in	 metabolic	 disorders,	 such	 as	 obesity,	
diabetes	mellitus,	liver	steatosis	and	cardiovascular	diseases	(Gong,	Sun,	and	Li	2009).	
The	 proteins	 isotypes	 are	 expressed	 differently	 throughout	 the	 tissues.	 CIDEB	 is	
expressed	mainly	in	liver,	and	in	smaller	amounts	in	kidney,	small	intestine	and	colon	
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(C.	Wu	et	al.	2008).	By	contrast,	CIDEA	and	CIDEC	are	mainly	expressed	in	the	adipose	
tissue,	regulating	the	formation	of	lipid	droplets	in	white	and	brown	adipocytes	(C.	Wu	
et	 al.	 2008).	 Additionally,	 CIDEA	 is	 expressed	 in	 the	mammary	 glands	of	 lactating	or	
pregnant	mice,	possibly	acting	as	a	transcription	coactivator	with	C/EBP	to	control	the	
expression	of	several	downstream	targets	(W.	Wang	et	al.	2012).	Finally,	CIDEC	(Fsp27)	
was	also	found	to	be	expressed	in	the	steatotic	and	fasted	liver(Vilà-Brau	et	al.	2013;	
Matsusue	et	al.	2008).	
3.1 Fat-specific	protein	27/CIDEC	isoforms	and	tissue-specific	
distribution		
	
Fat-specific	protein	27	(Fsp27)	was	originally	 identified	from	mouse	adipocyte	TA	cell	
lines	as	a	mature	adipocyte-specific	gene	(Danesch,	Hoeck,	and	Ringold	1992).	It	is	an	
important	 regulator	 of	metabolic	 homeostasis	 and	 it	 is	 involved	 in	 the	 regulation	 of	
FAO	 (Matsusue	 et	 al.	 2008).	 Nowadays	 there	 are	 two	 isoforms	 of	 FSP27	 described:	
alpha	 and	 beta.	 FSP27α 	 (CIDEC1	 in	 humans)	 is	 mainly	 expressed	 in	 WAT,	 while	
FSP27β (CIDEC2)	 is	 expressed	 in	 steatotic	 and	 fasted	 livers	 but	 it	 also	 is	 the	
predominant	 isoform	 in	 brown	 adipose	 tissue	 (BAT).	 Concretely,	 Fsp27β	 is	 highly	
expressed	 in	 the	 livers	 of	 ob/ob	 and	 fasted	 mice	 while	 in	 WAT	 the	 predominant	
isoform	 is	 Fsp27α,	 both	 in	 wild-type	 and	 ob/ob	 mice	 (Xu	 et	 al.	 2015).	 Despite	 the	
specific	 tissue	 distribution	 between	 isoforms,	 a	 deficiency	 in	 these	 proteins	 leads	 to	
the	 same	 lean	 phenotype;	 resistance	 to	 HFD	 induced	 obesity,	 improved	 insulin	
sensitivity	and	an	increased	whole	body	metabolic	rate	(L.	Z.	Wu	et	al.	2014;	Zhou	et	al.	
2003).		
	
The	 presence	 of	 two	 isoforms	was	 described	 through	 the	 characterization	 of	 CREBH	
knockout	mice	in	which	Fsp27	expression	fails	(J.	H.	Lee	et	al.	2011),	contrary	to	other	
CIDE	family	of	lipid	droplet	proteins	such	as	CIDEB,	or	Plin1,	which	expression	remains	
unaltered(Xu	et	al.	2015).	
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In	the	case	of	Fsp27,	although	its	mRNA	was	induced	by	CREBH	there	was	no	activation	
of	a	luciferase	reporter	containing	an	Fsp27	promoter	fragment	extending	from	-994bp	
to	 +23bp	 from	 the	 transcription	 start	 site.	 5’	 RACE	 experiments,	 using	 a	
complementary	primer	located	in	exon	3,	yielded	two	different	PCR	products	from	the	
liver	(Figure	I6).	This	data	led	to	the	identification	of	an	alternative	promoter	between	
exon	1	and	exon	2,	which	would	drive	the	transcription	of	an	alternative	Fsp27	mRNA	
(Fsp27β).	The	PCR	amplification	generated	a	single	product	in	mRNA	from	WAT	(the	α	
isoform).	 In	WAT	transcription	started	 in	exon	1a,	although	the	transcription-starting	
site	 was	 4	 bps	 downstream	 of	 the	 previously	 determined	 start	 site.	 In	 liver,	 the	
expressed	mRNA	starts	in	an	alternative	exon	1b	(Xu	et	al.	2015).	
	
	
		
Figure	 I6.	 Identification	 and	 characterization	 of	 alternative	 promoters	 for	 Fsp27	 transcription.	 Schematic	
representation	of	the	mouse	Fsp27	gene.	Boxes	denote	exons.	Dark	and	shaded	boxes	represent	protein-coding	and	
untranslated	regions,	respectively.	Arrows	indicate	transcription	start	sites	(Xu	et	al.	2015).	
	
Both	 isoforms	share	 the	 same	open	 reading	 frame.	However,	 FSP27β	 is	predicted	 to	
contain	10	additional	amino	acids	at	the	N-terminus,	which	allows	for	a	better	stability	
(Xu	et	al.	2015)	and	gives	different	characteristic	as	a	 lipid	droplet	 formation	protein	
(see	below).	The	characterization	of	the	two	transcriptions	start	site	can	explain	how	
liver	 Fsp27	 (Fsp27β)	 could	 be	 pharmacologically	 induced	 by	 PPARα	 ligands	 in	 liver	
(Langhi	 and	Baldán	 2014),	 despite	 its	 induction	 is	 not	 affected	 in	 starved	PPARα	 KO	
mice	 (Langhi	 and	 Baldán	 2014),	 since	 we	 know	 that	 CREBH	 is	 induce	 by	
PPARα activation	(Danno	et	al.	2010).		
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In	 summary	 Fsp27α	 promoter	 is	 regulated	 by	 C/EBP(Danesch,	 Hoeck,	 and	 Ringold	
1992),	 CREB	 (Vilà-Brau	 et	 al.	 2013)	 and	PPARγ (Matsusue	 et	 al.	 2008)	 in	WAT;	while	
Fsp27β	is	mainly	regulated	by	CREBH	in	liver	(Xu	et	al.	2015).		
	
Most	 of	 the	 data	 regarding	 Fsp27	 expression	 was	 obtained	 before	 knowing	 the	
existence	 of	 both	 isoforms.	 However,	 the	 strong	 tissue	 specific	 expression	 of	 both	
isoform:	 Fsp27β	 in	 liver,	 BAT	 and	 intestine,	 and	 Fsp27β in	 WAT	 makes	 possible	 to	
assume	old	data	in	the	new	context,	and	this	assumption	has	been	corroborated	in	this	
Thesis.	The	knowledge	about	the	isoform	existence	was	later	used	to	design	a	strategy	
to	obtain	Fsp27	tissue	specific	knock-out	(see	discussion).	
	
3.2 FSP27α 	and	β 	function	
	
	
LDs	are	dynamic	organelles,	constantly	forming,	growing	or	shrinking.	They	are	mostly	
formed	 in	 the	 endoplasmic	 reticulum	 (ER),	 where	 enzymes	 catalyzing	 neutral	 lipid	
synthesis	(e.g.,	acyl-CoA	cholesterol	acyltransferases	(ACATs)	for	sterol	esters	and	acyl	
CoA:	 diacylglycerol	 acyltransferases	 (DGATs)	 for	 TGs)	 predominantly	 reside	 (Natalie	
Krahmer,	 Farese,	 and	 Walther	 2013).	 	 In	 fatty	 acid	 excess	 conditions,	 LDs	 rapidly	
increase	their	volumes,	as	seen	for	example	 in	cell	culture	or	murine	small	 intestine.	
During	LD	growth,	the	synthesis	of	neutral	lipids	and	phospholipids	is	coordinated:	as	
LD	 volume	 increases,	 surfaces	 expand,	 and	 phospholipids	 are	 needed	 to	 shield	 the	
neutral	 lipid	core,	reduce	surface	tension,	and	prevent	LD	collapse	(N.	Krahmer	et	al.	
2011).	 Thus,	 changes	 in	 LD	 phospholipid	 composition	 are	 important	 in	 determining	
their	morphology	and	may	play	a	role	in	diseases	with	altered	lipid	storage.	
	
Originally,	 FSP27	was	 thought	 to	be	uniquely	 involved	 in	 the	 formation	of	unilocular	
lipid	 droplets	 in	 WAT	 during	 adipogenesis,	 as	 its	 expression	 was	 highly	 increased	
during	this	process	(Puri	et	al.	2007;	Nishino	et	al.	2008).	Both	alpha	and	beta	isoforms	
of	 FSP27	 are	 localized	 around	 the	 LDs,	 and	 therefore	were	 thought	 to	 promote	 the	
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formation	 of	 large	 LDs,	 and	 suppress	 lipolysis.	 However,	 they	 differ	 in	 the	 first	 10	
amino	acids	 residues	 and	 shown	 tissue-specific	 distribution;	 therefore,	 it	was	expect	
that	they	might	vary	in	their	specific	functions.		
	
The	 LD	 size	 is	 variable	 and	 their	 growth	 is	 thought	 to	 occur	 by	 two	 different	
mechanisms:	the	first	one	is	the	growth	of	LD	itself	(as	mentioned	before),	the	second	
one	is	by	fusion	of	the	already	existence	LDs.	In	this	context,	full	 length	FSP27	seems	
not	 to	 be	 necessary	 for	 the	 formation	 of	 large	 LDs	 (Tamori	 et	 al.	 2016),	 since	 LD	
expansion	depends	on	the	carboxy-terminal	domain	of	FSP27	(amino	acids	131-239).	
However,	the	amino-terminal	domain	of	FSP27	are	relevant	for	the	size	of	the	formed	
lipid	droplet	(Nishimoto	et	al.	2017).	
	
As	shown	in	Figure	I7,	FSP27	isoform	expression	can	regulate	lipid	droplet	size.	That	is	
an	 important	 issue	since	 it	can	determine	the	 fate	of	 the	accumulated	 fatty	acids.	 In	
WAT,	 FSP27α expression	will	 promote	 big	 unilocular	 lipid	 droplets	 that	 are	 ideal	 for	
efficient	 lipid	 storage	because	 lipolysis,	 from	 the	 LD	 surface,	 is	 restricted	due	 to	 the	
minimum	LD	surface	area.	 In	BAT,	FSP27β	expression	will	promote	small	multilocular	
LD	 formation,	 that	 is	 ideal	 for	efficient	 intracellular	 lipolysis	 from	the	LD	surface	and	
the	subsequent	facilitation	of	FFA	transport	to	mitochondria	that	are	adjacent	to	LDs	
for	β-oxidation	in	BAT(Nishimoto	et	al.	2017;	Nishimoto	and	Tamori	2017).	
	
INTRODUCTION	
	23	
	
Figure	 I7.	Proposed	mechanisms	by	which	 the	Cide	protein	 family	 regulates	 LD	 sizes	 in	WAT	and	BAT.	 In	WAT,	
FSP27a	on	neighboring	LD	induces	homo	dimerization,	resulting	in	the	fusion	of	LD,	subsequent	lipid	exchange,	and	
formation	of	larger	LD	(A).	CideA	also	mediates	the	formation	of	large	LD	in	the	same	manner	(B).	In	BAT,	FSP27b	
inhibits	the	homo	dimerization	of	CideA	and	suppresses	the	formation	of	large	LD	(C).	
	
	
In	concordance	with	this	working	model,	FSP27β	is	the	isoform	expressed	in	liver,	were	
FAO	has	to	occur	to	push	gluconeogenic	process.	However,	the	role	of	FSP27β	could	be	
more	sophisticated,	since	Fsp27β	expression	is	first	up	regulated	in	early	fasting,	and	
then	 down	 regulated	 during	 late	 fasting.	 Since	 CREBH,	 until	 now,	 is	 the	 only	 factor	
known	 to	 regulate	 Fsp27β	 expression,	 and	 CREBH	 is	 induce	 in	 both	 early	 and	 late	
fasting	 (see	 results),	 the	mechanism	controlling	Fsp27β expression	during	 fasting	still	
elusive	at	this	moment.	
	
4. REV-ERBα 	and	HNF6	in	lipid	metabolism	
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Rev-Erbα 	is	 a	 nuclear	 receptor	 that	 participates	 in	 the	 clock	 circuitry	 and	 regulates	
lipid	metabolism,	 adipogenesis	 and	 vascular	 inflammation	 (Duez	 and	 Staels	 2008).	 It	
was	 considered	 an	 “orphan	 receptor”	 due	 to	 its	 lack	 of	 known	 ligands,	 until	 the	
porphyrin	 heme	 was	 demonstrated	 to	 function	 as	 a	 ligand	 for	 both	 REV-ERBα 	 and	
REV-ERBβ  (Duez	and	Staels	2008;	Burris	2008).		
	
REV-ERBα	 and	 REV-ERBβ lack	 the	 activation	 function-2	 region,	 associated	 with	 the	
ability	 of	 nuclear	 hormone	 receptors	 to	 recruit	 co-activators	 and	 are	 considered	 as	
constitutive	repressors	of	transcription.	
	
Figure	I8.	Proposed	model	for	REV-ERB	as	a	repressor	of	transcription.(Burris	2008)	
	
The	 ligand	 heme	 modulates	 the	 activity	 of	 REV-ERB	 nuclear	 receptors,	 by	 binding	
directly	 to	 the	 ligand	binding	domain	 (LBD)	of	REV-ERB	and	 increasing	 its	affinity	 for	
the	 corepressor	 NCoR	 (Figure	 I8).	 This	 complex	 will	 lead	 to	 gene	 repression	 due	 to	
histone	 deacetylase	 activity	 from	 the	 nuclear	 receptor	 co-repressor	 (NCoR)/histone	
deacetylase	complex	(Burris	2008).	
	
Modulation	 of	 clock	 and	metabolism	by	 Rev-Erbα	 is	 accomplished	 through	 different	
pathways.	 To	 regulate	 clock	 control	 genes,	 it	 binds	 directly	 to	 the	 genome	 at	 its	
cognate	sites	competing	with	activating	ROR	transcription	factors;	on	the	other	hand,	
to	regulate	metabolic	genes	it	works	by	recruiting	the	histone	deacetylase	3	(HDAC3)	
through	 NCoR	 so	 its	 transcriptional	 repression	 effects	 are	 mediated	 through	 its	
interactions	with	DNA-bound	factors	(Y.	Zhang	et	al.	2015)	Deletion	of	HDAC3	or	REV-
ERBa	in	mouse	liver	causes	hepatic	steatosis	(Burstein	et	al.	2013).	
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More	 recently,	 it	 was	 described	 that	 REV-ERB〈 works	 cooperatively	 with	 the	
transcription	 factor	 HNF6	 to	 regulate	 hepatic	 lipid	 metabolism.	 The	 mechanisms	 of	
action	involve	the	HNF6	tethering	of	REV-ERBa	to	repress	lipid	metabolic	genes,	such	
as	Lp1,	Scd1,	Acacb,	Cd36	and	Fasn,	 that	are	up-regulated	 in	the	HNF6	knockout	and	
the	direct	activation	of	other	hepatic	genes	by	HNF6	(Y.	Zhang	et	al.	2016b).	
	
Thus,	 HNF6	 regulates	 hepatic	 lipid	metabolism	 in	 adult	 livers	 through	 a	mechanism	
that	 involves	 the	 HNF6-dependent	 tethering	 of	 REV-ERBα.	 Together	 they	 repress	 a	
variety	 of	 lipid	 metabolic	 genes	 that	 were	 shown	 to	 be	 up-regulated	 in	 the	 HNF6	
knockout.	HNF6	can	also	activate	directly	another	set	of	hepatic	genes.	
	
As	for	REV-ERBα,	besides	working	cooperatively	with	HNF6,	it	has	independent	effects	
on	 hepatic	 lipid	metabolism	 through	 tethering	 factors	 and	 on	 the	 regulation	 of	 the	
liver	circadian	clock,	as	seen	in	figure	I	6	(Y.	Zhang	et	al.	2016b).	
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1. Cell	Culture	
	
The	AML12	 (alpha	mouse	 liver	12)	cell	 line	was	established	from	hepatocytes	from	a	
mouse	(	CD1	strain,	line	MT42)	transgenic	for	human	TGF	alpha	and	it	exhibits	typical	
hepatocyte	features	such	as	peroxisomes	and	bile	canicular	like	structure.		
These	cells	were	a	kind	gift	from	Dra.	M.	Martinez	Chantar.	
The	 cells	 were	 cultured	 in	 a	 1:1	mixture	 of	 Dulbecco’s	Modified	 Eagle	Medium	 and	
Ham’s	F12	medium(DMEM:F12,	supplemented	with	0,005	mg/ml	insulin,	0,005	mg/ml	
transferrin,	 5	 ng/ml	 selenium,	 40	 ng/ml	 dexamethasone,	 4	 mM	 glutamine,	 100	
units/ml	 penicillin	 G,	 100ug/ml	 streptomycin,	 and	 heat-inactivated	 10%	 (v/v)	 Fetal	
Bovine	Serum	(FBS).	
	
The	HepG2	 (human	 liver	 carcinoma)	 cell	 line	was	 derived	 from	 the	 liver	 tissue	 of	 a	
fifteen	 years	 old	 male	 with	 differentiated	 hepatocellular	 carcinoma.	 These	 cells	 are	
adherent,	epithelial-like,	growing	as	monolayers	and	in	small	aggregates.	
The	 cells	were	 cultured	 in	Eagle’s	Minimum	Essential	Medium	 (MEM)	 supplemented	
with	 4	 mM	 glutamine,	 100	 units/ml	 penicillin	 G,	 100ug/ml	 streptomycin,	 and	 10%		
(v/v)	Fetal	Bovine	Serum	(FBS).	
	
The	HEK-293A	 cell	 line	 is	 a	 subclone	 of	 the	HEK-293	 (human	 embryonic	 kidney)	 cell	
line.	 Its	 relatively	 flat	morphology	 facilitates	 the	 initial	 production,	 amplification	 and	
tittering	 of	 replication-	 incompetent	 adenovirus.	 This	 cell	 line	 contains	 a	 stably	
integrated	copy	of	E1	gene	that	supplies	the	E1a	and	E1b	proteins	that	are	necessary	
to	generate	adenoviruses.	
The	cells	were	cultured	in	Dulbecco’s	Modified	Eagle	Medium	(DMEM),	supplemented	
with	 4	 mM	 glutamine,	 100	 units/ml	 penicillin	 G,	 100ug/ml	 streptomycin,	 and	 10%		
(v/v)	Fetal	Bovine	Serum	(FBS).	
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The	 cells	 were	 incubated	 at	 37oC	 in	 a	 humidified	 atmosphere	 containing	 5%	 CO2.	
Culture	medium	was	discarded	and	changed	each	2	 to	3	days.	To	pass	 the	cells,	 the	
plates	were	 rinsed	 twice	with	1x	PBS	and	a	0,05%	Trypsin-EDTA	solution	was	added.	
Once	the	cell	layer	was	dispersed	(from	2	to	5	minutes	at	37oC	depending	on	the	cell	
line),	the	trypsin	solution	was	deactivated	by	adding	complete	growth	medium.		
The	cells	were	either	split	in	a	1:3	dilution	every	3	days	or	counted	and	plated	for	the	
experiments.		
	
	
1.1 Reagents	used	in	Cell	Culture	
	
1.1.1 Cell	culture	maintenance	
		
	
Dulbecco’s	 Modified	 Eagle	 Medium	 and	 Ham’s	 F12	Medium	 (DMEM:F12)	 –	 GIBCO	
11320074 
Minimum	Essential	Medium	(MEM)	–	GIBCO	61100-087	
Dulbecco’s	Modified	Eagle	Medium	(DMEM)–	GIBCO	12100-061	
Fetal	Bovine	Serum	(FBS)	–	GIBCO	10270-106	
Penicillin	Streptomycin	(Pen	Strep)	–	GIBCO	15140-122	
Sodium	Bicarbonate	solution	7,5%	-	Sigma	Aldrich	S8761	
L-Glutamine	200	mM	–	GIBCO	25030-024	
Insulin-Trasnferrin-Sodium	Selenite	Supplement-	GIBCO	11074547001	
Dexamethasone	–	Sigma-Aldrich	D2915	
Tripsin-EDTA	10X	–	GIBCO	15400-054	
	
	
1.1.2 Cell	Culture	Transfection	
	
OPTI-MEM® 	I	Reduced	serum	media	–	GIBCO	31985-047	
Lipofectamine	LTX	Reagent	–	Invitrogen	15338-100	
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PLUS	Reagent–	Invitrogen	11514015	
1.1.3 Cell	Culture	Treatments		
WY14643	(Sigma,	C7081)	–	Selective	PPARα agonist,	dissolved	in	DMSO	to	10	mM.		
Hemin(Sigma-	Aldrich,	H9039)–	Natural	ligand	of	Reverbα.	Small	molecule	present	
either	free	or	bound	to	hemoglobin	in	the	bloodstream	of	mammals.	Dissolved	in	1.4M	
NaOH	to	30	mM.	
	
2. DNA	oligonucleotides	
	
All	of	the	DNA	oligonucleotides	mentioned	in	this	chapter	were	synthesized	by	Sigma-
Aldrich,	with	technology	ultra-high	base	coupling	efficiency,	combined	with	optimized	
cartridge	purification	and	100%	quality	control	by	mass	spectrometry.	
	
3. Vectors	
	
3.1 Cloning	vectors	
	
The	ampicillin	resistant	pGEM®-T	vector		(Promega	A36000)	is	linearized	by	digestion	
with	 the	 restriction	enzyme	EcoRV,	 and	has	additional	3’	 terminal	 thymidine	at	both	
ends.	 These	 3’-T	 overhangs	 facilitate	 the	 insertion	 of	 the	 PCR	 products	 with	 A	
overhangs	synthesized	by	the	Taq	polymerase.	
The	vector	contains	the	Sp6	and	T7	RNA	promoters,	that	flank	the	multiple	cloning	site	
with	several	restriction	sites.		
	
The	insertion	of	the	PCR	products	within	the	polylinker	disrupts	the	codifying	region	of	
the	 lacZ	 gene	 and	 the	 β-galactosidade	 activity.	 In	 a	 medium	 supplemented	 with	
ampicillin	 (100mg/L),	 IPTG	 (	8	mg/L)	and	X-Gal	 (	40	mg/L),	 the	 recombinant	 colonies	
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will	 be	 white,	 due	 to	 the	 impossibility	 to	 hydrolyse	 the	 X-gal	 substrate,	 while	 the	
colonies	that	 incorporated	the	empty	vector	will	be	blue,	due	to	the	presence	of	the	
products	of	the	X-gal	hydrolysis.	
	
3.2 Eukaryotic	Expression	Vectors	
	
The	pcDNA3	vector	 is	a	mammalian	expression	vector	with	the	CMV	promoter	and	a	
neomycin	resistance	marker.	
	
3.3 Reporter	vectors	
	
The	 reporter	vectors	are	used	 in	 the	 transitory	 transfection	of	eukaryotic	 cells.	After	
transfection,	the	enzymatic	activity	can	be	measured	by	chemiluminescence.			
	
The	pGL3Basic	 (Promega	E1751)	is	ampicillin	resistant	and	has	a	multiple	cloning	site	
upstream	 of	 the	 LUC	 gene.	 It	 does	 not	 have	 a	 eukaryotic	 promoter,	 or	 enhancer	
sequences;	 therefore	 the	 activity	 of	 the	 luciferase	 enzyme	 in	 the	 transfected	 cells	 is	
dependent	on	the	activity	of	the	inserted	promoter,	object	of	study.	
	
The	pRL-CMV	 (Promega	E2261)	 vector	 is	 a	wild-type	Renilla	 luciferase	 (Rluc)	 control	
reporter	vector.	
It	is	used	as	a	control	of	the	efficiency	of	mammal	cells	transfection.	
	
4. Plasmid	Constructs	
	
All	of	the	constructs	were	generated	by	PCR	from	mouse	genomic	DNA	from	C57BL/6,	
using	 Taq	 Polymerase	 (Biotools)	 and	 sequence	 specific	 primers	 (table	 1)	 introducing	
restriction	sites.	
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The	 correspondent	 PCR	 products	were	 cloned	 in	 the	 pGEM-T	 vector	 (Promega)	 and	
sequenced.		
The	plasmids	were	digested	with	the	corresponding	restriction	enzymes	and	subcloned	
into	pGL3b	vector	(Promega)	or	pCDNA3	vector.	
The	 sequences	 and	 orientations	 of	 the	 constructions	 were	 verified	 by	 sequencing	
(Macrogen	sequencing	service).	
	
The	 Fsp27β promoter	 (-900,	 +76,	 relative	 to	 +1β)	was	 amplified	by	PCR	 from	mouse	
genomic	DNA	using	 sequence	 specific	 oligonucleotides	 (table	 1)	 and	 cloned	 into	 the	
pGL3-basic	vector	(Promega),	using	the	restriction	sites	Xho	and	MluI.		
The	 Fsp27	 promoter	 including	 both	 α	 and	 β	 isoforms	 (Fsp27αβ-	 pGl3b)	 (-2024	 to	
+1013,	 relative	 to	 +1α),	 was	 amplified	 by	 PCR	 from	 mouse	 genomic	 DNA	 using	
sequence	 specific	 nulceotides	 (table	 1)	 and	 cloned	 into	 the	 pGL3-basic	 vector	
(Promega)	using	the	restriction	sites	XhoI	and	MluI.	
The	Fsp27β promoter	was	also	cloned	 including	different	deletions,	amplified	by	PCR	
from	mouse	genomic	DNA	using	sequence	specific	nucleotides	for	each	deletion	(table	
1)	and	cloned	into	the	pGL3basic	vector	using	the	restriction	sites	XhoI	and	MluI	:	
The	first	deletion	of	the	Fp27β promoter	(Fsp27β1-pGL3b)	comprised	660	nucleotides	
(-548,+76,	relative	to	+1β);	
The	 second	 deletion	 of	 the	 Fp27β promoter	 (Fsp27β2-pGL3b)	 comprised	 376	
nucleotides	(-300,+76,	relative	to	+1β);	
The	third	deletion	of	the	Fp27β promoter	(Fsp27β3-pGL3b)	comprised	166	nucleotides	
(-90,+76,	relative	to	+1β).	
	
	
Fsp27α	 cDNA	 was	 amplified	 by	 PCR	 from	 mouse	 cDNA	 using	 sequence	 specific	
oligonucleotides	 (Table	 1)	 and	 cloned	 from	 the	 translation	 initiation	 site	 ATG	 to	 the	
stop	codon	TGA	into	pcDNA3	expression	vector,	using	the	restriction	sites	HindIII	and	
EcorI.		
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Crebh-nuclear	cDNA	was	amplified	by	PCR	from	human	cDNA	using	sequence	specific	
oligonucleotides	(Table	1)	and	cloned	from	the	translation	site	ATG	to	the	stop	codon	
TGA	into	pcDNA3	expression	vector,	using	the	restriction	sites	XbaI	and	EcorI.		
Table	1.	Primers	for	PCR	amplification.	
	 Primers	Forward	(5’-3’)	 Primers	Reverse	
Fsp27b-pGL3b	 TTAACGCGTAGGAGCTGGGGTATATGGCT	 TTACTCGAGTGTTTCTCCGACCCAAGCTG	
Fsp27ab-pGL3b	 TTAACGCGTCTGCAACTCATTCTGTAGCCC	 TTACTCGAGTGTTTCTCCGACCCAAGCTG	
Fsp27a-	pcDNA3	 AAGCTTTGACAAGGATGGACTACGCC	 GAATTCACTCGGGTCTTCATTGCAGC	
Crebh-N-pcDNA3	 TTGAATTCCATCTGCAGACAGAACTGGATGG
AC	
AATCTAGATCATGTCTGGGCTGACTTGCTGGTGGAC	
Fsp27b1-pGL3b	 TTAACGCGTGTCCTTCTGCCAGTTATTGG	 TTACTCGAGTGTTTCTCCGACCCAAGCTG	
Fsp27b2-pGL3b	 TTAACGCGTTAGAAGTGCAGAGTCAGCTC	 TTACTCGAGTGTTTCTCCGACCCAAGCTG	
Fsp27b3-pGL3b	 TTAACGCGTTGACTTTCAGGTCCCTCACA	 TTACTCGAGTGTTTCTCCGACCCAAGCTG	
	
Mouse	 PPARα	expression	 vector	 (PPARα-pSG5)	was	 a	 gift	 from	 Dr.	 S.	 Green,	
Maclesfield.	
The	 thymidine	 kinase	 promoter	 under	 the	 control	 of	 three	 PPRE	 elements	 ((PPRE)3-
Tkluc)	was	a	gift	from	Dr.	F.Villaroya.	
Human	 RevErbα	 expression	 vector	 (pSG5-hRevErba)	 and	 human	 RORa1	 expression	
vector	(pSG5-RORa1)	and	was	a	gift	from	Dr.	J.C.	Rodríguez.	
	
The	 putative	 acetylation	 site	 of	 human	 CREBH,	 Lys294,	 was	 target	 of	 site-directed	
mutations.	Two	different	mutations	were	introduced,	the	K294R	mutation,	where	AAG	
changed	to	AGG,	or	K294Q,	where	AAG	changed	to	CAG.	The	site	directed	mutagenesis	
was	achieved	by	using	as	template	human	CREBH	expression	plasmid	and	the	primers	
described	in	table	2,	using	the	Q5	Site-directed	Mutagenesis	kit	(BioLabs)	following	the	
manufacturer’s	instructions.	
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Table	2.	Primers	used	for	the	site-directed	mutagenesis	of	human	CREBH	
	
	
5. Transient	transfection	and	Luciferase	assay	
	
Aml12	cells	were	seeded	at	a	density	of	4x104	cells/well	and	HepG2	cells	were	seeded	
at	a	density	of	6x104	cells/well,	 in	24-well	plates	and	transfected	using	Lipofectamine	
LTX	and	Plus	reagent	(Invitrogen),	following	the	manufacturer’s	instructions.	The	cells	
were	 co-transfected	 with	 400	 ng	 of	 the	 reporter	 gene	 construct	 (Fsp27β-pGl3b	 or	
(PPRE)3-TK-Luc)	 and	 	 between	 150	 to	 200	 ng	 of	 the	 eukaryotic	 expression	 vector	
(pcDNA3,	CREBH-N,	K294Q,	K294R,	Fsp27α,	PPARα,	RevErbα,	Sirt1,FoxA2,	FoxO3a).	10	
ng	of	the	plasmid	pRL-CMV	were	used	as	an	internal	transfection	control.		
The	total	amount	of	transfected	DNA	was	kept	constant	amongst	experimental	groups	
by	addition	of	empty	pcDNA3	plasmid.		
48h	 following	 transfection,	 cellular	 extracts	 were	 prepared	 for	 analysis	 of	 luciferase	
activity,	by	washing	the	cells	with	cold	PBS	and	harvesting	them	in	100	ul	of	1x	Passive	
lysis	buffer	(Promega).	A	10	ul	aliquot	of	the	the	lysates	were	collected		and	used	for	
Firefly	luciferase	assays,	using	the	dual	luciferase	reporter	assay	system	(Promega).		
Relative	 luciferase	 activity	was	 given	 as	 the	 ration	 of	 relative	 luciferase	 unit/relative	
Renilla	unit.	
	
	
	
Mutants	 Forward	Primers	(5’-3’)	 Reverse	Primers(5’-3’)	
K294Q	 GCATCTCGAGcagCAAAACCTGTC	 AAGACTTTCCTCTGTAACTCC	
K294R	 GCATCTCGAGaggCAAAACCTGT	 AAGACTTTCCTCTGTAACTCC	
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6. Recombinant	adenovirus	generation	
	
The	adenovirus	encoding	a	shRNA	against	Fsp27	was	generated	and	kindly	supplied	by	
Dr.	Ángel	Baldán.	
The	 adenovirus	 enconding	 a	 ShRNA	 control	 was	 purchased	 from	 Vector	 Biolabs	
(#1122),		and	contains	a	scramble	RNA	sequence	under	the	control	of	the	U6	promoter	
with	the	GFP	co-expression	under	CMV	promoter.		
6.1 Reagents	and	solutions	for	adenovirus	generation	
	
DMEM	10%	FBS	
Phosphate	buffer	solution	
CsCl	solution	(filter	sterilized/	-	10mM	TrisHCl	pH8	;	0,51g	CsCl/mL		
Adenovirus	 storage	 buffer	 2x	 (filter	 sterilized)	 –	 10mM	Tris	 pH8;	 10	mM	NaCl;	 0,1%	
BSA;50%	glycerol	
Dialysis	solution	pH8–	TBS/	30%	glycerol	(filter	sterilized)	
137	mM	NaCl;	20	mM	Tris	Base;30%	glycerol	(v/v)		
	
6.2 Adenovirus	amplification	
	
For	 the	 adenoviruses	 amplification,	 HEK-293A	 cells	were	 plated	 at	 10x106	 cells/flask	
(75cm2)	with	a	final	volume	of	15	mL	of	DMEM	10%	FBS.		
The	plated	cells	were	infected	from	6	to	15	hours	with	a	viral	dosis	of	10	pfu	(plaque	
forming	unit)	per	cell		(10x107)	per	flask.			
After	 the	 first	 24	 hours,	 the	 cells	 start	 to	 show	 morphological	 changes,	 starting	 to	
round	up	and	detach.	The	cells	are	recovered	between	24	and	48	hours	after	infection.	
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The	 recovered	 cells	 are	 centrifuged	 for	 10	 minutes,	 at	 4oC	 and	 1500	 rpm,	 and	 the	
pellet	is	ressuspended	in	a	final	volume	of	8	mL	of	PBS.		
To	cells	were	then	lysed	through	4	cycles	of	freezing,	with	a	mix	of	dry	ice	and	ethanol,	
and	defrosting,	in	a	37oC	bath.		
After	the	lysis,	the	cells	are	centrifuged	for	15	minutes,	at	4oC	and	5000	rpm,	and	the	
resulting	supernatant	is	recovered	to	a	15mL	corning	and	stored	at	-80oC.	
	
	
6.3 Adenovirus	purification	
	
For	in	vivo	use,	the	amplified	adenoviruses	must	be	purified.	
CsCl	was	added	to	the	amplified	adenoviruses	to	a	 final	density	of	1,34g/mL	and	the	
mix	was	transfered	to	quickseal	polyallomer	tubes	(Beckman	342413)	with	the	aid	of	a	
syringe.	 The	 tubes	 were	 filled	 to	 the	 top	 with	 an	 already	 prepared	 and	 sterilized	
solution	with	the	corrected	density	of	1,34g/ml.	
Both	tubes	were	carefully	sealed	and	centrifuged	overnight	at	a	temperature	of	22oC,	
with	a	Beckam	NVT	65	rotor,	at	6300	rpm.	The	centrifuge	was	set	with	no	brakes.	
After	centrifugation,	the	tube	containing	the	adenovirus	was	carefully	punctured	and	
the	opaque	viral	band	was	recovered	with	a	3	mL	syringe	set	with	an	18	gauge	needle,	
and	transferred	to	new	quickseal	polyallomer		tubes,	filled	with	the	CsCl	solution	and	
centrifuged	at	a	temperature	of	22oC	for	5	hours,	at	6300	rpm.	The	centrifuge	was	set	
with	no	brakes.	
After	 centrifugation	 the	adenoviral	band	was	 recovered	 from	each	 tube	with	a	1	mL	
syringe	set	with	a	21	gauge	needle	and	transferred	into	a	Slide-A-lyzer	dialysis	cassette	
(Pierce	#66370),	adding	an	equivalent	volume	of	adenovirus	storage	buffer	2x.	
The	solution	was	dialyzed	overnight	in	TBS	30%	glycerol,	agitating	and	at	4oC.	
Recover	the	next	day	and	store	at	-80oC.	
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6.4 Adenovirus	tittering	
	
To	quantify	 the	viral	 stock,	HEK-293A	cells	were	plated	with	a	density	of	1x105	cells/	
well	in	a	12	multi-well.	
The	cells	were	infected	with	a	series	of	dilutions	of	the	adenovirus	(from	10-3	to	10-8).		
48h	 after	 the	 infection	 the	 cells	 were	 observed	 in	 a	 fluorescence	 microscope	 (the	
adenovirus	 expressed	 the	 green	 fluorescence	 protein)	 and	 the	 green	 cells	 were	
counted.		
The	 calculation	 of	 the	 viral	 stock	 was	 obtained	 counting	 the	 cells	 (	 x20	 lens)	 in	 3	
different	fields.	The	following	equation	was	used	to	obtain	pfu/mL:	
	
Pfu/ml=((infected	cells/field)x594)/	(0,1x	dilution	factor)	
	
7. Animal	Experiments	
	
For	the	in	vivo	experiments,	mice	were	used.	The	mice	were	housed	in	cages	on	a	12h	
light:	12h	dark	cycle	at	controlled	temperature	(25±1).	
All	experiment	protocols	with	mice	were	performed	with	 the	approval	of	 the	animal	
ethics	committee	of	the	Universitat	de	Barcelona,	Barcelona,	Spain.	
	
	
7.1 Fasting	Kinetics	Experiment	
	
10	week-old	 C57BL/6J	male	mice	 (supplied	 by	 Charles	 River)	 were	 used.	Mice	were	
divided	in	two	groups,	one	fed	Ad	Libitum	(ZT12)	with	a	standard	chow	diet	or	fasted	
for	6h	(ZT18),	15h	(ZT13)	or	24h	(ZT12)	and	euthanized	at	the	indicated	Zeitgeber	time	
(ZT).	
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7.2 High	Fat	Diet	experiment	
	
For	 the	 comparison	 of	 Fsp27β	 expression	 between	 the	 fed	 and	 fasted	 state,	 with	 a	
control	 and	high	 fat	 diet	 in	mice	 liver,	 12	week-old	male	mice	with	mix	 background	
c57bl6/sv129,	where	used.	The	mice	were	either	fed	Ad	Libitum	or	fasted	for	24	h.	
These	mice	were	a	kind	gift	from	Toni	Vidal-Puig	lab	from	the	University	of	Cambridge.	
	
For	the	comparison	of	Fsp27α	and	Fsp27β expression	throughout	different	tissues	10	
week-old	C57BL/6J	male	mice	were	used.	Mice	were	divided	in	two	groups,	one	fed	a	
standard	chow	(CHO	62%;	Prot	17%;	Fat	17%)	and	the	other	fed	a	High-Fat	diet	(CHO	
25%;	 Prot	 15%;Fat	 60%)	 for	 21	weeks.	 Both	diets	 contained	 the	 same	proportion	of	
micronutrients	to	avoid	effects	that	did	not	derived	from	the	difference	in	fat.	
The	mice	were	fasted	for	8	hours	before	being	euthanized.		
	
7.3 FSP27	knockdown	Experiments	
	
Adenoviruses	encoding	shRNA	control	or	a	shRNA	against	Fsp27	(kindly	supplied	by	Dr.	
Ángel	Baldán,	SLU)	were	administered	to	8	week	old	C57Bl/6J	male	mice	by	 tail-vein	
injection	(5x109	pfu/animal).		
Nine	days	after	injection,	mice	were	either	fed	ad	libitum	with	a	standard	chow	diet	(7	
animals	per	group,	both	control	and	shFsp27)	or	fasted	for	17h	(6	animals	per	group,	
both	 control	 and	 shFsp27)	 and	euthanized	at	 ZT5	 (i.e.	 5h	after	 the	onset	of	 the	12h	
light	span)	and	sacrificed	at	the	indicated	Zeitgebertime	(ZT).		
	
7.3.1 Tissues	Harvesting	
 
Mice	were	fully	anesthetized	using	isoflurane	inhalation	(4%	for	induction	and	2%	for	
maintenance),	the	thoracic	cavity	was	opened	and	blood	was	collected	by	intracardiac	
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puncture.	 After	 sacrificing	 the	 animals,	 tissues	 were	 isolated	 and	 immediately	 snap	
frozen	in	liquid	nitrogen.	Tissues	were	stored	at	-80oC	for	future	analysis.	
	
7.3.2 Serum	extraction	
		
Mice	 serum	 was	 obtained	 by	 clotting	 whole	 blood	 (30	 minutes,	 RT)	 following	 a	
centrifugation	 (1500G,	 15	 min,	 4oC).	 Serums	 were	 stored	 at	 -80oC	 for	 posterior	
analysis.	
	
	
7.3.3 Phospholipids	measurements	
	
7.3.3.1 Solid	Phase	Extraction	Method		
Serum	 samples	 were	 diluted	 with	 PBS	 followed	 by	 a	 liquid/liquid	 extraction	 with	
methanol	 and	 a	 solution	 of	 the	 internal	 standard	 (16:0D31-18:1	 PC)	 in	 chloroform	
(final	 concentrations	of	 PBS:	MeOH:	CHCl3	were	 1:1:2).	 The	mixture	was	 thoroughly	
vortexed	 and	 then	 centrifuged	 at	 10,000	 rpm	 to	 provide	 two	 liquid	 phases	 (one	
aqueous	 layer	on	the	top	and	an	organic	 layer	at	the	bottom)	separated	by	a	disk	of	
white	 solid	 material.	 An	 aliquot	 of	 the	 lipid-containing	 layer	 (organic	 phase)	 was	
evaporated	 to	 dryness	 using	 a	 constant	 stream	 of	 nitrogen	 and	 re-dissolved	 in	
hexane/methyl-tert-butyl-ether	 (MTBE)/acetic	 acid	 (100:3:0.3)	 followed	 by	
fractionation	using	a	column	purification	method,	as	described	(24).	Briefly,	Bond	Elut	
SS-NH2	 cartridges	 (3	ml,	 500	mg,	 47-60	mm,	Varian)	were	equilibrated	3	 times	with	
acetone/water	(7:1)	and	washed	with	two	1	ml	portions	of	hexane.	Lipids	were	loaded	
onto	 the	 column	 and	 were	 eluted	 sequentially	 with	 hexane,	 hexane/CHCl3/AcOEt	
(100:5:5),	 CHCl3/iPrOH	 (2:1),	 CHCl3/MeOH/AcOH	 (100:2:2)	 and	 finally	 the	
phospholipid	 fraction	 was	 eluted	 with	 CHCl3/MeOH/H2O	 (5:10:4),	 evaporated	 to	
dryness	 under	 a	 stream	 of	 nitrogen	 and	 reconstituted	 with	 CHCl3	 prior	 to	 LC-MS	
analysis.	
MATERIALS	AND	METHODS	
	40	
	
7.3.3.2 LC–ESI–MS/MS	procedure	
	
The	HPLC	 system	consisted	of	 an	Agilent	1290	 Infinity	 (Waldbronn,	Germany)	 binary	
pump	 equipped	 with	 a	 thermostated	 (10	 °C)	 autosampler.	 For	 the	 analysis	 of	 the	
extracts,	a	Mediterranea	Sea	C18	column	(100	×	2.1	mm,	2.2	μm)	(Teknokroma)	was	
used,	 mantained	 at	 50	 °C.	 Mobile	 phase	 A	 consisted	 of	 95:5	 water:methanol	 and	
mobile	phase	B	was	composed	of	60:35:5	 isopropanol:methanol:water.	Both	A	and	B	
were	 supplemented	with	0.1%	 formic	 acid	 and	5	mM	ammonium	 formate.	 The	 flow	
rate	was	0.5	ml	min-1	and	the	injection	volume	2	μl.	A	linear	gradient	profile	with	the	
following	proportions	of	solvent	B	was	applied	(t,	%B):	 (0,	20),	 (5,	20),	 (20,	100),	 (25,	
100),	(26,	20),	(35,	20).	MS/MS	experiments	were	performed	on	an	QTRAP	6500	mass	
spectrometer	(AB	SCIEX,	Concord,	Ontario,	Canada).	All	the	analyses	were	performed	
using	the	 IonDrive™	source	 in	positive	 ion	mode	with	the	following	settings:	capillary	
voltage	5500	V,	temperature	500	ºC,	curtain	gas	(N2)	25	(arbitrary	units),	GS1	(N2)	50	
(arbitrary	units),	GS2	 (N2)	30	 (arbitrary	units),	 collision	gas	Medium	 (arbitrary	units),	
declustering	potential	(DP,	Table	3),	entrance	potential	10	V,	collision	energy	(CE,	Table	
3),	 collision	 cell	 exit	 potential	 (CXP,	 Table	 3).	 All	 the	 MS/MS	 parameters	 were	
optimized	in	infusion	experiments:	individual	standard	solutions	of	18:0-18:1	PC,	16:0-
18:1	PC	and	16:0D31-18:1	PC	(100	ng	μl−1)	were	infused	at	a	constant	flow	rate	of	5	μl	
min−1	 into	 the	mass	 spectrometer.	 Relative	 quantification	 of	 phosphocoline	 species	
was	 done	 using	 stable	 isotope	 dilution	 mass	 spectrometry	 with	 the	 spectrometer	
operated	 in	MRM	 (multiple	 reaction	 monitoring	 method).	 Transitions	 were	 used	 to	
identify	and	quantify	the	analyses	(Table	3).	
	
Table	3.	Transitions	used	to	identify	and	quantify	the	analyses	of	mass	spectrometry.	
Compound	 Transitions	 DP	 CE	 CXP	
18:0-18:1	PC	 788.5/184.0	
788.5/85.9	
196	
196	
39	
101	
18	
10	
16:0-18:1	PC	 760.6/184.1	 171	 39	 16	
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760.6/86.1	 171	 101	 10	
16:0D31-18:1	PC	 791.6/184.1	
791.6/86.0	
136	
136	
41	
103	
10	
10	
	
The	 integrated	 peak	 area	 for	 each	 species	 was	 normalized	 to	 the	 peak	 area	 of	 the	
internal	standard.		 	
	
7.3.4 Triglyceride	measurements		
Lipids	 from	 the	 livers	of	mice	were	extracted	with	5%	NP40/ddH2O	and	TG	 levels	 in	
livers	 and	 serums	were	 analyzed	with	 a	 TG	measurement	 kit	 (LabAssay	 Triglyceride	
Wako).	
7.3.5 RNA	analysis	
	
7.3.5.1 RNA	extraction	
	
Frozen	 tissues	were	 chopped	 in	 liquid	 nitrogen	 and	 crushed	 in	 TRI	 Reagent	 solution	
with	 the	 help	 of	 a	 politron	 and	 the	 RNA	 was	 isolated	 following	 the	manufacturer’s	
instructions.	
The	 RNA	 was	 pre	 treated	 with	 DNAse	 I	 (Ambion)	 to	 eliminate	 genomic	 DNA	
contamination	and		
dissolved	 in	 DEPC-water	 (Sigma-Aldrich)	 and	 the	 concentration	 and	 purity	 of	 each	
sample	 was	 obtained	 from	 A260/A280	 and	 A260/A230	 measurements	 in	 a	 micro	
volume	 spectrophotometer	 Nanodrop-1000	 (Nanodrop	 Technologies,	 Inc.	 Thermo	
Scientific).	
7.3.5.2 Analysis	of	mRNA	expression	
	
The	 cDNAs	 were	 prepared	 from	 total	 RNA	 of	 tissues	 and	 were	 subjected	 to	
quantitative	real	time	polymerase	chain	reaction	(qPCR)	to	measure	the	mRNA	levels	
of	the	genes	of	interest,	using		SYBR	Green	or	Taqman	reagents.	
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One	 microgram	 of	 total	 RNA	 was	 used	 to	 synthesize	 the	 cDNA	 by	 M-MLV	 reverse	
transcriptase	 (Invitrogen)	 with	 random	 hexamers	 (Roche	 Diagnostics)	 and	 dNTPs	
(Attend	Bio)	according	to	manufacturer’s	instructions.		
The	 SYBR	 Green	 PCR	 Master	 Mix	 and	 Taqman	 Gene	 Expression	 Master	 Mix,	 was	
supplied	by	Applied	Biosystems	(ThermoFisher	Scientific)	and	used	for	the	PCR	step.	
Amplification	 and	detection	were	performed	using	 the	 Step-One	Plus	Real-Time	PCR	
System	(Applied	Biosystems,	ThermoFIsher	Scientific).	
The	PCR	assays	were	carried	out	 in	96-well	plates	and	each	mRNA	single	sample	was	
measured	in	duplicate	using	18S,	beta-actin	and	b2m	as	housekeeping	genes.	
The	 results	were	obtained	by	 the	Relative	Standard	Curve	Method	and	expressed	as	
the	Ct	method	and	expressed	as	fold	increase	versus	the	experimental	control.	
The	probes	(table	6)	and	primers	(table	7)	used	are	shown	below:	
	
Table	4.	qPCR	probes	for	Taqman	assays	
	
	
	
	
	
	
	
	
Table	5.	qPCR	primer	pairs	for	Sybr	green	assays.	
Name	 Forward	Primers	(5’-3’)	 Reverse	primers	(5’-3’)	
B2M	 ACTGATACATACGCCTGCAGAGTT	 TCACATGTCTCGATCCCAGTAGA	
Cpt1b	 GCGTGCCAGCCACAATTC	 TCCATGCGGTAATATGCTT	
Fsp27α 	 GCCACGCGGTATTGCCAGGA	 TCCATGCGGTAATATGCTT	
Fsp27β 	 TGACCACAGCTTGGGTCGGA	 TCCATGCGGTAATATGCTT	
Ucp1	 CCCGCTGGACACTGCC	 ACCTAATGGTACTGGAAGCCTGG	
Name	 Probes		
mCpt2	 Mm00487202_m1	
mFgf21	 Mm00840165_g1	
mFsp27	 Mm00617672_m1	
mHMGCS2	 Mm00550050_m1	
18S	 X03205.1	
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18S	 CGGCTACCACATCCAAGGAA	 GCTGGAATTACCGCGGCT	
	
	
	
	
8. Statistical	analysis		
All	 results	are	expressed	as	mean	±	SEM.	Significant	differences	were	assessed	using	
the	two-tailed	Student’s	t-test.	P	<0,05	was	considered	statistically	significant.	
	
	
9. Additional	Information		
	
Any	 missing	 information	 regarding	 the	 experimental	 procedures	 means	 that	 the	
procedure	was	performed	according	to	the	detailed	 information	given	by	“Molecular	
Cloning,	a	Laboratory	Manual”	(Sambrook,	Frisch	and	Maniatis)	and	“Current	Protocols	
in	Molecular	Biology”	(Ausubel,	Bent,	Kingston,	Moore,	Seidman,	Smith	and	Struhl)	or	
fol	
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1. Regulation	of	FSP27	during	the	fasting	adaptation		
	
Fsp27	 is	 a	 response	 gene	 in	 the	 fasted	 liver,	 it	 has	 a	 particular	 expression	 pattern,	
showing	 changes	 in	 liver	during	 the	 fasting	period	by	 increasing	at	 the	beginning	 (6-
15h)	and	lowing	in	the	long	fasting	(24h)	(Vilà-Brau	et	al.	2013).	For	this	reason,	it	was	
important	 to	 study	 the	mechanisms	underlying	 this	 regulation,	 as	 explained	 in	more	
detail	below.	
	
1.1 	Expression	pattern	of	Fsp27α 	and	Fsp27β 	in	different	tissues			
Two	different	isoforms	(FSP27α	and	FSP27β),	differing	in	the	first	10	amino	acids	and	
driven	by	different	promoters	are	expressed	from	the	same	gene	(Xu	et	al.	2015).	 In	
order	 to	 compare	 the	mRNA	 expression	 of	 both	 isoforms	 in	 different	 tissues	 under	
fasting	 conditions	we	perform	a	 gene	 expression	 analysis	 through	 a	 qPCR	 approach.	
C57BL6/KJ	mice	were	fed	with	a	control	diet	(CD)	or	a	HFD	for	21	weeks	and	the	mRNA	
levels	were	evaluated	in	various	tissues	after	12h	fasting.		Figure	R1	shows	that	FSP27β	
is	the	isoform	mainly	expressed	in	BAT,	small	 intestine	and	liver	in	animals	fed	either	
with	a	control	diet	(CTL)	or	with	a	HFD.	
RESULTS	
	 	48		
Figure	R	1.	Expression	 levels	of	Fsp27α  (white	bars)	and	Fsp27β (black	bars)	 in	different	tissues.	-	RT-PCR	analysis	of	
Fsp27a	and	Fsp27b	C57BL/6J	mice	fed	with	a	control	diet	(CTL)	or	HFD	for	21	weeks	and	starved	for	12	hours	before	
sacrifice	(n=8)	in	A,B)	BAT,	C,D)	small	intestine	and	E,F)	liver.	As	the	comparison	were	performed	in	the	same	tissue	the	
values	represented	are	absolute	quantifications	rather	than	relative	 levels.	Error	bars	represent	the	mean	±standard	
error	of	the	mean	(SEM)	*	p	<0,05	and	***	p	<	0,001relative	to	the	expression	of	Fsp27α .	
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1.2 	Expression	pattern	of	Fsp27β 	in	the	adaptation	to	fasting		
	
In	 2013,	 our	 group	described	 the	hepatic	 expression	pattern	of	Fsp27	during	 fasting	
adaptation	 (Vilà-Brau	 et	 al.	 2013).	 These	 results	 were	 published	 before	 the	 two	
different	isoforms	were	described.	As	FSP27β	is	the	main	isoform	expressed	in	liver	we	
analyzed	the	expression	pattern	of	the	beta	isoform	of	the	Fsp27	gene	during	a	fasting	
time-course	experiment.	This	way,	the	specific	expression	and	the	regulation	of	Fsp27β	
in	the	adaptation	to	fasting	could	be	evaluated,	as	it	was	done	before	with	total	Fsp27.	
Fsp27β	 and	Fsp27α	mRNA	 levels	were	measured	 in	 livers	of	 fasted	mice	at	different	
time	 points	 (0,	 6,	 15	 and	 24	 hours).	 As	 figure	 R	 2	 shows,	 Fsp27β	 has	 the	 same	
expression	pattern	as	total	Fsp27	(Vilà-Brau	et	al.	2013).	As	the	mRNA	of	alpha	isoform	
was	not	detected	 in	 liver	 (data	shown)	 this	experiment	confirmed	that	FSP27β	 is	 the	
main/unique	isoform	expressed	in	fasted	in	liver	and	also	the	responsible	of	the	Fsp27	
role	in	the	fasting	adaptation	of	the	liver	metabolism.		
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Figure	R	2.	Fsp27β 	is	a	responsive	gene	in	the	fasted	liver.	mRNA	levels	of	Fsp27β  in	the	livers	of	fasted	mice	(n=5	
per	group),	at	different	time	periods	(black	bars:	Ad	Libitum,	white	bars:	6	hours	fasting,	light	grey	bars:	15	hours	
fasting,	dark	grey	bars:	24	hours	fasting).	Error	bars	represent	the	mean	±standard	error	of	the	mean	(SEM)	.	*	p<	
0,05	and	***	p<0,001	relative	to	Fsp27β 	expression	Ad	Libitum;	#	p<0,05	relative	to	Fsp27β 	expression	at	6	hours	
fasting.	
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1.3 	Impact	of	a	High-Fat	diet	on	the	expression	of	Fsp27β  		
Fsp27β	expression	is	induced	under	different	nutritional	inputs,	HFD,	MD,	but	also	by	
fasting.	To	explore	how	Fsp27β	is	regulated	by	both	HFD	and	fasting,	an	in	vivo	
experiment	using	C57Bl6/J	mice	was	designed.	Animals	were	divided	into	four	
different	groups.	In	two	of	the	groups	the	mice	were	fed	Ad	Libitum	either	CD	or	a	
HFD;	in	the	remaining	two	groups,	the	mice	were	also	fed	a	CD	or	a	HFD,	but	were	
fasted	12h	before	being	sacrificed.		
This	experiment	combines	the	adaptation	to	fasting	and	a	HFD	(Figure	R3)	to	a	better	
understanding	of	Fsp27	regulation,	as	it	is	not	only	a	possible	regulator	in	the	adaption	
to	fasting	but	it	is	also	expressed	in	the	steatotic	liver,	under	the	regulation	of	PPARγ.	
(Matsusue	et	al.	2008)	
									
	
Interestingly,	and	although	Fsp27β is	already	significantly	up	regulated	in	fasting	when	
the	 mice	 were	 previously	 fed	 with	 a	 CD,	 its	 expression	 is	 much	 higher	 in	 a	 fasting	
condition,	when	fed	previously	with	a	HFD.	
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Figure	R	3.	Fsp27β 	is	fasting	dependent	and	up	regulated	by	a	HFD.	Gene	expression	(mRNA	levels)	in	the	livers	of	
fed	and	fasted	mice,	previously	fed	a	control	or	HFD	(white	bars:	Fed,	control	diet;	light	grey	bars:	Fasted,	control	
diet;	dark	grey	bars:	Fed,HFD	black	bars:	Fasted,	HFD.	Error	bars	represent	the	mean	±standard	error	of	the	mean	
(SEM)	.	**	p<	0,01	and	***	p<0,001	relative	to	Fsp27b	expression	Fed,	control	diet;	##	p<0,01	relative	to	
Fsp27β 	expression	fasted,	control	diet.	
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Nonetheless,	 no	 significant	 changes	 are	 seen	 between	 the	mice	 fed	 a	 CD	 and	 HFD,	
meaning	that	possibly	the	pattern	of	expression	of	Fsp27	 is	always	fasting	dependent	
(Figure	R3).	
	
2. Transcriptional	regulation	of	Fsp27	in	liver		
	
To	 study	 its	 importance	 in	 the	 adaptation	 to	 fasting	 and	 thus	 have	 a	 better	
understanding	of	FSP27	expression	pattern,	its	transcriptional	regulation	was	studied.	
Globally	the	experimental	approach	used	to	solve	this	part	of	the	work	was	based	on	
transient	 transfection	 assays.	 A	 hepatic	 cell	 line	 model	 (AML12)	 was	 used	 to	 co-
transfect	 luciferase	 reporter	 constructs	 that	 include	 different	 regions	 of	 the	 Fsp27	
promoters	 with	 various	 combinations	 of	 plasmids	 that	 codify	 for	 the	 transcription	
factors	we	were	interested	on.		
	
	
2.1	CREBH	and	Rev-Erba	as	possible	Fsp27	regulators	in	fasting	
	
	
The	focus	of	this	part	of	the	study	was	to	understand	by	which	mechanisms	Fsp27β	is	
up	 regulated	 in	an	early	 fasting	and	down	regulated	 in	a	 late	 fasting.	As	 for	 the	 first	
part	of	the	question,	the	proposed	responsible	for	the	up-regulation	of	Fsp27β	 is	the	
transcription	 factor	 Cyclic-AMP-responsive-element-binding-protein	 H	 (CREBH).	 For	
the	 second	 part,	 lower	 induction	 in	 late	 fasting,	we	 proposed	 either	 the	 acetylation	
levels	of	CREBH	or	Rev-Erbα expression.	
In	 figure	 R	 4,	 the	 mRNA	 expression	 pattern	 of	 CREBH	 (Figure	 R	 4A)	 and	 REV-ERBα	
(Figure	R	4B)	were	analyzed,	at	the	same	fasting	times	as	Fsp27β	(Figure	R	3),	to	check	
if	these	two	factors	are	implied	in	the	mRNA	changes	of	Fsp27β.	
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Figure	R	4.	CREBH	and	Rev-Erbα 	are	possible	Fsp27β 	regulators	(A)	CREBH	and	(B)	Rev-Erbα  gene	expression	in	
the	livers	of	fasted	mice,	at	different	time	periods	(black	bars:	Ad	Libitum,	white	bars:	6	hours	fasting,	light	grey	
bars:	15	hours	 fasting,	dark	grey	bars:	24	hours	 fasting).	Error	bars	 represent	 the	mean	±standard	error	of	 the	
mean	(SEM)	*	p<	0,05	and	**p<	0,01	relative	to	expression	Ad	Libitum.			
In	figure	R	4A,	the	CREBH	mRNA	expression	is	induced	constantly	during	the	course	of	
the	 fasting	 period,	 therefore	 showing	 an	 up-regulation	 in	 fasting	 state.	 As	 for	 Rev-
Erbα, its	expression	pattern	shown	in	figure	R	4	B	 illustrates	that	 its	mRNA	levels	are	
opposite	 to	 the	 Fsp27β	 levels.	 Rev-Erbα, is	 down-regulated	 in	 an	 early	 fasting	 (6	
hours),	being	this	tendency	reversed	in	a	late	fasting,	once	the	levels	rise	at	15	hours	of	
fasting,	and	keep	rising.	This	profile	would	be	compatible	with	the	possible	role	of	REV-
ERBα	as	a	FSP27β	repressor.	Consequently,	arises	the	hypothesis	that	FSP27	regulation	
could	be	due	to	the	PGC1α-Rev-Erbα axis.	In	addition,	It	is	also	reported	that	Rev-Erbα	
negatively	 affects	 Fgf21	 expression	 by	 a	mechanism	 that	 involves	 the	 expression	 of	
ALAS-1,	the	rate	limiting	enzyme	in	heme	biosynthesis	(Estall	et	al.	2009).	
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2.1 	Fsp27	promoter	
		
The	two	isoforms	of	FSP27	have	different	tissue	expression	patterns	and	their	mRNA	
levels	 are	 regulated	 by	 different	 signals	 and	 transcription	 factors.	 Looking	 for	 the	
response	 elements	 that	 were	 responsible	 to	 the	 transcriptional	 regulation	 of	 FSP27	
expression	and	moreover	 this	differential	expression	pattern,	 the	promoter	of	FSP27	
and	the	differential	regulatory	elements	between	both	isoforms	were	analyzed.		
	
As	it	is	shown	in	figure	R	5,	the	Fsp27	promoter	contains	different	response	elements,	
marked	 in	 figure	 R	 5,	 along	 with	 the	 Fsp27α	 transcription	 starting	 site	 (+1α)	 and	
Fsp27β	transcription	starting	site	(+1β).		
	
Concretely,	 it	 contains	 two	different	putative	CREB	 response	elements,	CRE	 (-1792,	 -	
1787	relative	to	+1α	and		-375,-366	relative	to	+1α),	a	PPAR	response	element,	PPRE	(-
116,	-1150		relative	to	+1b)	and	a	CREBH	response	element,	CHRE	(-35,-24	relative	to	
+1b).	Additionally,	in	figure	R	5	it	is	also	marked	a	predicted	site	for	REV-ERBα,	outside	
the	range	of	the	constructs	assayed.	
		
Figure	R	5.	Map	of	total	Fsp27β 	promoter	(-2024,	+1013	relative	to	+1b)	,	with	the	Fsp27α 	transcription	starting	
site	(+1a)	and	Fsp27β 	transcription	starting	site	(+1b),	the	two	putative	CREB	response	elements	CRE2	(-1792,-
1787	relative	to	+1a)	and	CRE1	(-375,	-366	relative	to	+1a),PPAR	response	element	PPRE	(-1163,-1150	relative	to	
+1b)	and	CREBH	response	element	(-35,-24relative	to	+1b)	and	a	predicted	Rev-Erba	putative	binding	site	.	
	
	
In	the	course	of	this	study,	different	constructs	of	the	promoter	driving	the	luciferase	
gene	 expression	 were	 used	 (Figure	 R6).	 The	 Fsp27αβ construct	 (-2024	 to	 +1013	
relative	 to	 +1α) includes	 both	 transcription	 starting	 sites	 (+1α	 and	 +1β)	 and	 the	
elements	 of	 response	 for	 CREB	 (CRE),	 PPAR	 (PPRE)	 and	 CREBH	 (CHRE).	 The	 Fsp27α	
construct	(-2024,	+13	relative	to	+1α)	encodes	for	the	alpha	isoform,	and	contains	the	
response	elements	for	CRE	and	PPRE.	Finally,	to	study	more	specifically	the	regulatory	
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elements	 that	 control	 Fsp27β	 expression	 various	 constructs	 with	 different	 deletions	
encoding	 for	 the	 β	 isoform	 and	 containing	 the	 CHRE	 response	 element	 were	
generated:	The	Fsp27β(-900)	(-900	to	+76	relative	to	+1β),	Fsp27β(-584)	(-584	to	+76,	
relative	to	+1β),	Fsp27β(+300) (-300	to	+76	relative	to	+1β),	Fsp27β(-90)	 (-90	to	+	76	
relative	to	+1β).		
	
	
	
	
	
2.2 	Fsp27β 	is	a	CREBH	but	not	a	PPARα 	target	gene			
As	 stated	 above,	 there	 is	 a	 CHRE	 site,	 a	 CREBH	 response	 element	 in	 the	
Fsp27β promoter,	and	consequently	CREBH	is	an	activator	of	the	alternative	β	isoform.	
The	 promoter	 sequence	 described	 for	 Fsp27α contains	 a	 PPRE	 element,	 that	 is	 not	
present	 in	 the	 specific	 promoter	 sequence	 for	 the	β	 isoform.	 In	 order	 to	 study	 the	
effects	of	both	CREBH	and	PPARα in	the	regulation	of	Fsp27,	the	Fsp27β promoter	was	
co-transfected	 in	 AML12	 cells	 with	 CREBH	 and	 PPARα (Figure	 R	7A).	 Although	 the	
Figure	 R	 6.	 Map	 of	 the	 different	 Fsp27	 promoter	 constructs.	 (A)	 Fsp27αβ 	 (-2024	 +1013	 relative	 to	 +1β )	
containing	the	CREB	responsive	elements	CRE	(-1792,-1787	relative	to	+1a	and	-375,	-366	relative	to	+1α ),	PPAR	
response	element	PPRE	(-1163,-1150	relative	to	+1β)	and	CREBH	response	element	 (-35,-24	relative	to	+1β )	;	
(B)	Fsp27α(2024,	+18	relative	to	+1α )containing	the	CREB	responsive	elements	CRE	(-1792,-1787	relative	to	+1α 	
and	-375,	-366	relative	to	+1α),	PPAR	response	element	PPRE	(-1163,-1150	relative	to	+1β )	and	(C)	Fsp27β(-
900,+76	 relative	to	 +1β),	 (D)	Fsp27β (-584,+76	 relative	to	 +1β),	 (E)	Fsp27(-300,	+76	relative	 to	+1β)	and	(F)	
Fsp27β 	(-90,	+76	relative	to	+1β )	,	CREBH	response	element	(-35,-	24	relative	to	+1β ).	
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promoter	 is	 activated	 by	 CREBH,	 there	 is	 no	 effect	 of	 PPARα,	 neither	 on	 the	
promoter’s	basal	activity,	nor	in	the	CREBH	activated	promoter.	
	
	
	
The	 same	 assay	 was	 performed	 using	 the	 Fsp27αβ promoter	 (Figure	 R	 7B),	 that	
contains	the	PPRE	response	element,	and	the	same	results	were	observed.		
Therefore,	this	data	indicates	that	Fsp27	is	a	CREBH	but	not	a	PPARα	target	gene.	
		
2.3 Fsp27β 	activation	is	dependent	on	CREBH	acetylation	
	
The	fasting	dependent	CREBH	acetylation	is	crucial	for	 its	transcriptional	activity.	The	
acetylation	and	deacetylation	of	CREBH	are	catalysed	by	the	 lysine	acetyl	transferase	
PCAF	 and	 the	 deacetylase	 SIRT1,	 respectively	 (Hyunbae	 Kim	 et	 al.	 2015b).	 This	
information	led	to	the	hypothesis	that	Fsp27	down-regulation	in	late	fasting	could	be	
due	to	deacetylation	of	CREBH,	making	the	modulation	of	Fsp27	activity	dependent	of	
the	lysine	acetylation	of	CREBH.	
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Figure	 R	 7.	 Fsp27	 promoter	 is	 activated	 by	 CREBH	 but	 not	 by	 PPARα . 	(A)	 Fsp27β  and	 (B)	 Fsp27αβ 	 promoter	
activation	in	AML12	cells	co-transfected	with	the	transcription	factors	CREBH	and	PPARa.	Values	are	given	as	±	s.d.	
***p<0,001	relative	to	Fsp27	promoter’s	basal	activity.		
RESULTS	
	 	56	
	
To	pursue	this	hypothesis	two	different	mutants	were	generated,	the	mutant	K294Q,	
mimicking	the	acetylated	state	of	CREBH,	and	the	deficient	acetylation	mutant	K294R.			
These	 mutants	 were	 transfected	 in	 AML12	 cells	 with	 the	 Fsp27β	 reporter	 plasmid	
(Figure	R	8).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
The	mutant	 K294Q	 showed	 similar	 effects	 as	 the	wild-type	 CREBH	Nuclear,	 and	 the	
K294R	acetylation	deficient	mutant	K294R	failed	to	induce	Fsp27β in	the	same	extent.	
	
These	 results	 point	 out	 that	 Fsp27β	 activation	 by	 CREBH	 is	 dependent	 on	 its	
acetylation	state.	
	
	
2.4 	The	role	of	REV-ERBα 	and	HNF6	in	Fsp27	repression	
	
As	shown	before,	REV-ERBα	is	a	possible	candidate	for	the	repression	of	FSP27,	due	to	
its	pattern	of	expression	 in	 fasting	 (Figure	R	4B).	 To	evaluate	 this	hypothesis	AML12	
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Figure	R	8.	Regulation	of	Fsp27β  is	 dependent	on	 the	acetylation	 state	of	 CREBH.	Fsp27β 	 promoter	 activity	 in	
AML12	cells	co-transfected	with	wild	type	CREBH	and	the	mutants	K294Q	and	K294R.	Error	bars	represent	the	
mean	±standard	error	of	the	mean.	***	p<0,001	relative	to	the	promoter’s	basal	activity	and	##	p<0,01	relative	
to	the	promoter	activation	by	CREBH.	
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cells	 were	 co-transfected	 with	 the	 Fsp27β	 promoter,	 CREBH	 and	 REV-ERBα. In	
this	context,	REV-ERBα was	not	able	 to	 repress	 the	promoter	activation	produced	by	
CREBH	(Figure	R	9).		
	
	
	
	
	
	
	
	
	
	
Moreover,	 both	 the	 Fsp27αβ	 and	 the	 Fsp27β	 promoter	 were	 co-transfected	 with	
RORα,	 a	 transcription	 factor	 that	 competes	 for	 the	 same	binding	 sites	 as	REV-ERBα,	
but	no	effect	was	shown	(Figure	R	10).	This	data	indicates	that	REV-ERBα may	not	be	a	
direct	repressor	for	FSP27.	
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Figure	R	9.	Fsp27αβ 	 regulation	 through	CREBH	and	REV-ERBa.	Fsp27β 	promoter	 (-900	to	+76,	 relative	to	
+1B)	 activity	 in	 AML12	 cells	 co-transfected	 with	 the	 transcription	 factors	 CREBH	 and	 REV-ERBa.	 Values	 are	
given	as	mean	±	s.d	**	p<	0,01	relative	to	Fsp27β 	promoter’s	basal	activity.	
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Based	 on	 the	 results	 that	 indicate	 that	 REV-ERBα	 is	 not	 a	 direct	 repressor	 of	 the	
Fsp27β	 promoter	 and	 knowing	 that	 REV-ERBα	 works	 cooperatively	 with	 the	
transcription	 factor	 HNF6	 to	 regulate	 the	 hepatic	 lipid	 metabolism	 (Y.	 Zhang	 et	 al.	
2016a)	 AML12	 cells	 were	 co-transfected	 with	 the	 Fsp27β	 promoter	 and	 the	 HNF6	
transcription	 factor,	 CREBH	 and	 REV-ERBα. Although	 REV-ERBα	 itself	 cannot	 repress	
the	activation	shown	by	CREBH,	HNF6	repressed	the	promoter	activity	(Figure	R	12).		
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Figure	R	10.	Fsp27	promoter	activation	does	not	depend	on	ROR.	(A)	Fsp27β 	promoter	(-900	to	+76,	relative	to	
+1B)	and	(B)	Fsp27aβ(-2024	+1013	relative	to	+1β )	activity	in	AML12	cells	co-transfected	with	the	transcription	
factor	ROR.	
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With	 this	 result,	 the	 next	 step	 was	 to	 map	 the	 HNF6	 putative	 binding	 site,	 that	 is	
predicted	to	be	at	-155	to	-141	relative	to	+1β, performing	deletions	of	the	promoter	
as	 detailed	 previously	 (Figure	 R	 6).	 The	 different	 constructs	 (Fsp27β(-584),	 Fsp27β(-
300)	and	Fsp27β(-90))	were	transfected	in	AML12	cells	with	or	without	HNF6,	as	seen	
in	figure	R	13	A,B	and	C,	respectively.	In	figure	R	13C,	the	shorter	promoter	construct,	
Fsp27β (-90)	 does	 not	 loss	 its	 activation	 by	 CREBH	 completely,	 but	 it	 is	 significantly	
reduced.	 	Since	the	construct	Fsp27β (-90)	should	exclude	the	HNF6	putative	binding	
site,	this	result	raises	the	question	of	whether	HNF6	is	acting	directly	on	the	promoter	
or	is	involved	in	an	indirect	response.	In	figure	R	13D,	an	experiment	was	performed	to	
test	 the	 effect	 of	HNF6,	 by	 co-	 transfecting	 different	 amounts	 of	 CREBH	and	 a	 fixed	
concentration	 of	 HNF6.	 The	 result	 shows	 that	 the	 effect	 of	 HNF6	 depends	 on	 the	
CREBH	concentration,	meaning	that	it	is	probably	a	squelching	phenomenon	between	
CREBH	and	HNF6.	
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Figure	R	11.	HNF6	as	a	possible	Fsp27β 	 repressor.	Fsp27β 	promoter	 (-900	to	+76,	 relative	to	+1B)	 activity	 in	
AML12	cells	co-transfected	with	the	transcription	factors	HNF6,	REV-ERBα 	and	CREBH.	Error	bars	represent	the	
mean	±standard	error	of	the	mean	*	p<0,05;	**	p<0,01	and	***	p<0,001	relative	to	the	promoter’s	basal	activity	
and	#	p<0,05	relative	to	the	promoter’s	activation	by	CREBH.	
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Finally	 and	 looking	 for	 the	 role	 of	 REV-ERBα we	 analyzed	 the	 results	 of	 a	 ChIPseq	
experiment	published	by	Mitchell	Lazar’s	group	(GSM1659686).	They	used	livers	from	
129S1/SvlmJ	 mice	 to	 extract	 protein	 and	 performing	 the	 chromatin	
immunoprecipitation	with	a	REV-ERBα antibody. After	After	 the	 immunoprecipitation	
through	 the	 DNA	 sequencing	 it	 is	 possible	 to	 check	 the	 enriched-regions	 and	 to	
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Figure	R	12.	HNF6	affects	FSP27β 	regulation,	through	CREBH.	 (A)	Fsp27β (-584)	(-584	to	+76,	 relative	to	+1β),	
(B)	Fsp27β (-300)	(-300	to	+76,	relative	to	+1β ),	(C)	Fsp27β(-90)	(-90to	+76,	relative	to	+1β)	activity	in	AML12	
cells	co-transfected	with	the	transcription	factors	HNF6	and	CREBH	co-transfected	with	the	same	amount	of	each	
transcription	factor	and	(D)	Fsp27β (-90)	 (-90to	+76,	 relative	 to	+1β )	activity	 in	 a	dependent	dosis	of	 CREBH.	
Values	are	given	as	±	s.d.**	p<0,01	and	***	p<0,001	relative	to	 the	promoter’s	basal	activity	and	###	p<0,005	
relative	to	the	promoter’s	activation	by	CREBH.		
A)	 	B)	
C)	 D)	
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identify	where	REV-ERBα	binds.	The	result	of	this	analysis	 indicates	that	Reverbα has	
indeed	 some	 putative	 binding	 sites	 on	 the	 Fsp27	 promoter	 (Figure	 R	 11),	 although	
these	sites	(approximate	coordinates	-3070	to	-133	relative	to	+1β)	are	outside	of	the	
range	of	the	Fsp27	promoter	constructs	used	in	this	thesis.		
	
	
	
	
3. The	role	of	FSP27	as	a	lipid-droplet	protein	in	PPARα 	
signaling		
PPARα	is	an	important	regulator	of	the	FAO,	although	its	regulation	mechanism	is	not	
clearly	understood.	While	PPARα	 is	 activated	 in	 feeding	periods,	and	not	by	adipose	
stores	 (Chakravarthy	 et	 al.	 2005),	 its	 target	 genes	 are	 expressed	 in	 fasting	 but	 its	
expression	is	impaired	when	FASN	is	absent	(FASKOL).	Nowadays	two	phosphocholines	
(16:0/18:1	 and	18:0/18:1)	 has	been	described	as	 PPARα	 ligands	 (Chakravarthy	 et	 al.	
2010)(S.	 Liu	et	 al.	 2013).	 Therefore,	 this	may	uncover	a	 link	between	Fsp27,	with	 its	
Figure	R	13.	Analysis	 of	 ChIP-seq	 results	 from	Mitchell’s	 Lazar	 group	 (GSM1659686);	 showing	 sequences	 enrichment	
after	immunoprecipitation	of	Rev-ERBα	is	shown	in	green.	WT:	liver	of	C57BL/6J	mouse.	129	mice:liver	of	129S1/SvlmJ.	
DBDmut:	liver	of	C57BL/6J	RevErba	DNA	binding	domain(DBD)	mutant	mouse.	FSP27/CIDEC	representation	is	shown	in	
blue.	
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particular	expression	pattern	(Vilà-Brau	et	al.	2013)	and	with	its	role	in	the	unilocular	
lipid	droplet	formation	and	the	availability	of	PPARα	ligands.	
	
To	 determine	 the	 role	 that	 FSP27	 plays	 in	 PPAR	 signaling,	 two	 different	 approaches	
were	used,	in	vitro	and	in	vivo.		
	
	
3.1 Interference	of	PPARα 	signaling	by	Fsp27β 	in	vitro	
	
For	the	first	approach,	a	hepatic	cell	line	model	(HepG2)	was	used	to	transfect	the	TK	
(thymidine-kinase)	 luciferase	 reporter	 construct	 under	 the	 control	 of	 three	 PPRE	
(peroxisome	proliferator	responsive	element).		The	cells	were	co-transfected	with	the	
expression	vector	for	PPARα,	FSP27α,	and	both	of	the	constructs	simultaneously.	
											
Figure	R	14	corroborates	that	FSP27	is	somehow	involved	in	the	regulation	of	PPARα,	
by	disturbing	PPARα	activation	of	the	TK	promoter.	This	disturbance	is	reversed	in	the	
presence	of	a	synthetic	agonist	of	PPARα	(Wy14643),	revealing	that	in	these	conditions	
Figure	R	14.	FSP27	interferes	with	PPAR	signaling.		TK	luciferase	reporter	activity	in	HepG2	cells	co-transfected	
with	PPARα 	and	FSP7α .	Error	bars	represent	the	mean	±standard	error	of	 the	mean	.	***<	0,001	relative	to	
the	promoter’s	basal	activity	and	###	<	0,005	relative	to	the	promoter	co-transfected	with	PPARα 	and	FSP27α,	
with	DMSO.	
	
RESULTS	
	 	 63	
PPARα	activation	may	be	mediated	by	endogenous	ligands.	This	result	evidences	that	
although	Fsp27	is	not	a	direct	PPARα	target	gene,	it	may	interfere	indirectly	in	its	
signaling.	
	
	
3.2 	Effects	of	hepatic	FSP27β 	absence	in	PPAR	signaling	in	vivo	
	
To	 evaluate	 the	 role	 of	 FSP27β	 expression	 in	 PPAR	 signaling	 in	 vivo,	 its	 hepatic	
expression	 was	 knocked-down	 in	 fed	 and	 starved	 animals,	 by	 using	 an	 adenovirus-
mediated	 shRNA.	 The	mice	were	divided	 in	 two	different	 groups,	 the	 control	 group,	
with	 a	 shRNA	 control	 adenovirus	 and	 the	 shFSP27	 group,	 with	 a	 shRNA	 silencing	
FSP27.		
	
The	 experiment	 was	 conducted	 in	 two	 different	 conditions,	 Ad	 Libitum,	 and	 at	 17	
hours	fasting.	This	time	frame	was	chosen	by	combining	the	Fsp27	expression	pattern	
(Vilà-Brau	et	al.	 2013)	 and	 the	variation	of	 the	phospholipids	 in	 serum,	described	as	
PPARα	endogenous	ligands.	(S.	Liu	et	al.	2013)	
	
	
3.2.1 Fsp27β	hepatic	knockdown		
	
The	 success	 of	 the	 experimental	 design	 was	 confirmed	 by	 analysis	 of	 the	 mRNA	
expression	of	Fsp27β	in	the	livers	of	mice.		
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As	 expected,	 there	 is	 an	 increase	 in	 the	expression	of	 the	hepatic	Fsp27β	 in	 fasting,	
concomitant	with	Fsp27	pattern	of	expression	in	this	condition	(Vilà-Brau	et	al.	2013),	
relative	to	the	control	ad	libitum	mice.	In	both	conditions,	there	is	a	significant	down-
regulation	 of	 the	 gene	 expression	 both	 Ad	 Libitum	 and	 in	 the	 17	 hours	 fasting,	
meaning	that	the	knockdown	was	successful	(Figure	R	15).	
	
	
3.2.2 Hepatic	Fsp27β expression	is	essential	for	liver	long-term	
expression	of	PPARα	target	genes	
	
After	analysis	of	PPARα target	genes	mRNA	expression,	it	is	confirmed	that	silencing	of	
FSP27	 affects	 the	 expression	 of	 genes	 like	 Fgf21	 and	Hmgcs2	 (Figure	 R	 17A	 and	 B,	
repectively)	,	showing	that	their	induction	in	fasting	is	dependent	on	Fsp27	expression.		
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Figure	R	15.	Successful	Fsp27β 		hepatic	knockdown.	Fsp27β  gene	expression	in	the	livers	of	mice	fed	Ad	Libitum	
or	 fasted	 for	 17	 hours	 treated	with	 shRNA	 control	 adenovirus	 (CTL:	white	 or	 dark	 grey	 bars,	 respectively)	 or	
shFsp27	specific	adenovirus	(shFSP27:	light	dark	or	dark	respectively).	Error	bars	represent	the	mean	±standard	
error	of	the	mean	(SEM)	*<0,05	and	***<	0,001	relative	to	Ad	Libitum	control;	#	<	0,05	relative	to	fasting	control.	
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Unexpectedly,	the	expression	of	Cpt2,	an	early-fasting	responsive	gene,	is	not	altered	
(Figure	 R	 16C).	 	 Therefore,	 it	 seems	 that	 FSP27	 only	 affects	 the	 expression	 of	 late	
fasting	responsive	PPARα	target	genes.	
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Figure	R	 16.	 Effects	 of	 hepatic	 Fsp27β 	 knockdown	 in	 liver.	 Gene	 expression	 in	 the	 livers	 of	mice.	 (A)	 Fgf21,	 (B)	
Hmgcs2,	 (C)	Cpt2.	Mice	were	 fed	Ad	Libitum	or	 fasted	for	 17	hours	treated	with	 shRNA	 control	 adenovirus	 (CTL:	
white	or	dark	grey	bars,	respectively)	or shFsp27	specific	adenovirus	(shFSP27:	light	dark	or	dark	respectively).	Error	
bars	represent	the	mean	±standard	error	of	the	mean	(SEM)	**<0,01	and	***<	0,001	relative	to	Ad	Libitum	control;	
#	<	0,05	and	##	<	0,01	relative	to	fasting	control.	
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3.2.3 Hepatic	FSP27β expression	affects	serum	phospholipids	levels		
	
In	 17	 hours	 fasting,	 the	 TAG	 levels	 in	 serum	 rise	 in	wild	 type	 animals,	 although	 this	
does	not	occur	in	the	mice	lacking	hepatic	fsp27β	(figure	R	17A).	In	liver,	there	is	also	a	
rise	in	the	TAG	levels	in	fasting,	and	it	can	be	concluded	that	FSP27β	is	essential	for	the	
accumulation	of	TAG,	both	in	the	fed	and	the	fasted	state	(Figure	R	17b).	
	
	
	
	
	
	
When	analyzing	the	serums	of	the	animals,	it	was	discovered	that	the	concentration	of	
phospholipids	 was	 lower	 in	 fasted	 animals	 in	 comparison	 with	 the	 fed	 animals.	
Nonetheless,	 in	 the	 animals	 lacking	 hepatic	 Fsp27β,	 the	 levels	 of	 phospholipids	 in	
serum	 are	 higher,	 in	 both	 conditions	 (Figure	 R	 18).	 These	 two	 results	 put	 together	
suggest	 that	 Fsp27β	 expression	 is	 essential	 to	 accommodate	 TAG	 in	 liver	 and	 to	
preserve	the	phospholipids	needed	for	the	formation	of	the	lipid	droplets.	
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Figure	 R	 17.	 Fsp27	 hepatic	 knockdown	 alters	 TAG	 levels.	 (A)	 Serum	 levels	 (mg/dL)	 and	 (B)	 liver	 levels	 (mg/g	
tissue)	of	 TAG.	Mice	were	 fed	Ad	 Libitum	or	 fasted	 for	 17	hours	treated	with	 shRNA	 control	 adenovirus	 (CTL:	
white	or	dark	grey	bars,	 respectively)	or	shFsp27	 specific	adenovirus	(shFSP27:	 light	dark	or	dark	respectively).	
Values	are	given	as	mean	± 	SEM	*<0,05	relative	to	Ad	Libitum	control;	#	<	0,05	relative	to	fasting	control.	
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3.2.4 Hepatic	Fsp27β	expression	affects	the	expression	of	PPARα	target	
genes	in	Brown	Adipose	Tissue	
	
The	 increase	 in	 the	 levels	 of	 phospholipids	 in	 serum	 of	 Fsp27β	 knockdown	 animals	
(Figure	R	18)	correlates	with	a	decrease	in	PPARα	 late	fasting	responsive	genes,	such	
as	Fgf21	and	Hmgcs2	(Fig	16).	Therefore,	it	is	possible	that	endogenous	PPARα	ligands	
are	 being	 secreted	 from	 the	 liver,	 losing	 lipid	 droplet	 formation	 capacity.	 To	 further	
study	 the	 implications	 of	 the	 absence	 of	 Fsp27β	 in	 liver,	 the	 expression	 pattern	 of	
PPARα	target	genes	were	also	studied	in	BAT	and	muscle	(Figure	R	19).	
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Figure	R	18.	Fsp27	hepatic	knockdown	alters	phospholipids	(PC)	levels.	(A)	Serum	levels	(ug/L)	of	1-	palmitoyl-2-
oleoyl-sn-glycerol-3-phosphocholine	(PC	18:0/18:1)	;	(D)	Serum	levels	(ug/L)	of	1-stearoyl-2-oleoyl-sn-glycerol-3-
phosphocholine	 (PC	 16:0/18:1).	Mice	were	 fed	Ad	 Libitum	or	 fasted	 for	 17	 hours	 treated	with	 shRNA	 control	
adenovirus	(CTL:	white	or	dark	grey	bars,	respectively)	or	shFsp27	specific	adenovirus	(shFSP27:	light	dark	or	dark	
respectively).	Error	bars	 represent	the	mean	±standard	error	of	 the	mean	 (SEM)	*<0,05	relative	to	Ad	Libitum	
control;	#	<	0,05	relative	to	fasting	control.	
RESULTS	
	 	68	
	
	
	
	
	
CTL	 ShFsp27	 CTL	 ShFsp27	
Ad	Libitum	 Fasted	17h.	
CTL	 ShFsp27	 CTL	 ShFsp27	
Ad	Libitum	 Fasted	17h.	
0,0	
0,2	
0,4	
0,6	
0,8	
1,0	
1,2	
1,4	
m
RN
A	
	re
la
pv
e	
ev
el
s	(
fo
ld
s)
	 Ucp1	(BAT)	
        
***	
				#	
(A)	
0,0	
0,5	
1,0	
1,5	
m
RN
A	
re
la
pv
e	
le
ve
ls
	(f
ol
ds
)	
Fgf21	(BAT)	
								**				
    
#
						#	
(B)	
0,0	
0,2	
0,4	
0,6	
0,8	
1,0	
1,2	
m
RN
A	
re
la
pv
e	
le
ve
ls
	(f
ol
ds
)	
Cpt1b	(BAT)	
  ***   
#
					
							#	
(C)	
0,0	
0,5	
1,0	
1,5	
m
RN
A	
re
la
pv
e	
le
ve
ls
	(f
ol
ds
)		
Cpt2	(BAT)	
*	
0,0	
0,5	
1,0	
1,5	
m
RN
A	
re
la
pv
e	
le
ve
ls
	(f
ol
ds
)	
Fsp27β (BAT)	
          
						#	
									**			
(E)	
0	
0,5	
1	
1,5	
m
RN
A	
re
la
pv
e	
le
ve
ls
	(f
ol
ds
)	 Cpt1b	(muscle)	
								
	**	
			**	
(F)	
(D)	
Figure	R	19.	Effects	of	liver	knockdown	in	extra-hepatic	tissues.	Gene	expression	in	BAT	and	muscle		soleus	of	
mice	 fed	Ad	Libitum	or	 fasted	for	17	hours	treated	 	with	shRNA	control	adenovirus	 (CTL:	white	or	dark	grey	
bars,	 respectively)	 or	 shFsp27	 specific	adenovirus	 (shFSP27:	 light	dark	or	dark	respectively).	 (A-E)	BAT	Ucp1,	
Fgf21,	Cpt1b,	Cpt2,	Fsp27b,	respectively.	 (F)	Muscle	Cpt1b.	Error	bars	represent	the	mean	±standard	error	of	
the	mean	(SEM)	*<0,05,	**<	0,01	and	***<	0,001	 relative	 to	Ad	 Libitum	control;	 #	<	 0,05	 relative	to	 fasting	
control.	
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Fasting	down	regulates	UcpI	(Figure	R	19A),	Fgf21	(Figure	R	19B),	Cpt1b	(Figure	R	19C)	
and	Cpt2	(Fig	19D)	in	BAT,	and	this	down	regulation	is	partially	restored	in	the	BAT	of	
the	shFsp27β	animals	were	the	phospholipids	levels	in	serum	are	increased,	except	for	
Cpt2.	 In	 Figure	 R	 19	 Fsp27β	 is	 down	 regulated	 by	 fasting	 and	 up	 regulated	 by	 liver	
knockdown.	In	muscle,	fasting	down	regulates	Cpt1b,	but	this	effect	is	independent	of	
the	expression	of	Fsp27β		in	liver	or	phospholipids	in	serum.		
	
Globally,	 these	 results	 suggest	 that	during	 fasting,	PPARα ligands	are	accumulated	 in	
the	steatotic	liver,	preventing	an	excessive	PPARα	activity	in	BAT.	
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At	the	beginning	of	the	1960s,	a	diverse	group	of	pesticides	(clofibrate)	was	recognized	
as	capable	of	causing	the	proliferation	of	peroxisomes	in	rat	liver.	Subsequently,	it	was	
identified	 that	 these	 compounds	 bound	 to	 a	 nuclear	 receptor	 that	 was	 known	 as	
peroxisome	proliferator	activated	receptor	(PPAR).	
	
We	now	know	 that	 the	endogenous	 ligands	of	PPAR	are	 the	 fatty	acids,	or	products	
derived	 from	 them	 like	 certain	 prostaglandins.	 PPARs	 are	 the	way	 to	 regulate	 gene	
expression	according	to	the	availability	of	fatty	acids.	
The	 three	PPARs,	PPARα,	 PPARβ/δ	 and	PPARγ,	 show	distinct	 tissue	distributions	and	
regulate	 various	 aspects	 of	 lipid	metabolism.	 The	 best-described	 functions	 for	 these	
receptors	 include	 the	 adipogenic	 and	 insulin-sensitizing	 effects	 of	 PPARγ	 and	
regulation	of	fatty	acid	catabolism/mitochondrial	oxidative	metabolism	by	PPARα	and	
PPARδ	 in	 liver	 and	 muscle,	 respectively.	 In	 the	 liver,	 PPARα	 and	 PPARδ	 exhibit	
opposing	activities	in	the	control	of	diurnal	lipid	metabolism.	PPARα is	up-regulated	in	
the	fasted	state	to	regulate	fat	catabolism	(Kersten	et	al.	1999).	By	contrast,	PPARδ	is	
more	 active	 in	 the	 fed	 state	 and	 controls	 the	 transcription	 of	 lipogenic	 genes	
(Sanderson	et	al.	2010;	S.	Liu	et	al.	2011;	S.	Liu	et	al.	2013).	
	
The	most	 important	 contribution	 to	 identify	 the	 endogenous	 ligands	 of	 PPARα	 was	
made	in	the	FASKOL	animal	model	(Chakravarthy	et	al.	2005).	This	animal	is	unable	to	
synthesize	 fats,	 and	 when	 fed	 with	 a	 zero	 fat	 diet	 and	 subjected	 to	 fasting,	 is	
hypoglycemic.	 In	 fact,	 this	 model	 shows	 a	 phenotype	 similar	 to	 a	 fasted	 PPARα	
knockout	 animal.	 By	 pharmacologically	 activating	 PPARα 	 in	 the	 FASKOL	mice,	 these	
effects	 were	 reversed.	 Thus,	 it	 can	 be	 said	 that	 metabolic	 abnormalities	 in	 FASKOL	
mice	are	driven	by	the	failure	to	activate	PPARα	(Chakravarthy	et	al.	2005).	
	
Therefore,	 in	 the	absence	of	dietary	 fat,	 FAs	 synthesized	de	novo	 through	FAS	 (fatty	
acid	 synthase)	are	able	 to	act	 as	PPARα ligands	 (Chakravarthy	et	 al.	 2005).	 Later	on,	
the	 phospholipid	 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine	 (16:0/18:1	 GPC)	
has	 been	 identified	 as	 an	 endogenous	 ligand	 with	 nanomolar	 affinity	 for	
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PPARα (Chakravarthy	et	al.	2010).	This	observation	supports	the	model	that	only	“new	
fat”,	 either	 from	 the	 diet	 or	 from	 FAS-dependent	 synthesis,	 and	 not	 the	 “old	 fat”	
recruited	from	peripheral	stores,	produces	PPARα	ligands.	Down	regulation	(siRNA)	of	
CEPT1	(Kennedy	pathway)	decreased	the	expression	of	PPARα-dependent	genes,	that	
were	rescued	by	exogenous	16:0/18:1-GPC.	This	 line	of	evidence	indicates	that	when	
16:0/18:1-GPC	binds	to	PPARα	in	the	nucleus	it	activates	the	transcription	machinery,	
inducing	 the	 expression	 of	 PPARα-dependent	 genes	 and	 affecting	 lipid	
metabolism(Chakravarthy	et	al.	2010).	
	
However,	 this	model	 generates	 a	 new	 paradox	 in	 the	 PPAR	 field.	 The	 expression	 of	
PPARα	 is	 circadian	 (Lemberger,	Desvergne,	 and	Wahli	 1996),	with	a	decrease	of	 this	
receptor	 protein	 in	 the	 fed	 state	 and	 an	 increase	during	 fasting,	 coinciding	with	 the	
need	 for	 FA	 oxidation	 to	 maintain	 the	 energy	 balance.	 Since	 the	 16:0/18:1	 GPC	
production	and	peak	of	PPARα	 activity	are	anti-phasic,	 it	 could	be	postulated	 that	 if	
FAS	is	essential	for	producing	the	PPARα	ligand,	then	additional	regulation	is	required	
to	present	the	ligand	to	PPARα	when	needed.	In	this	Thesis,	we	are	proposing	that	this	
additional	mechanism	 could	be	 related	with	 lipid	 droplet	 formation	during	 the	 early	
fasting	period	(see	below).	
	
The	physiological	role	of	PPARδ has	been	more	elusive,	although	today	we	know	that	
expression	of	PPARδ	in	liver	is	a	key	element	in	the	production	of	lipids	necessary	for	
the	activation	of	PPARα	in	liver	and	muscle.		
	
PPARδ	 shows	 an	 ubiquitous	 pattern	 of	 expression.	 In	 muscle	 it	 is	 attributed	 a	
fundamental	 role	 in	 the	 regulation	 of	 mitochondrial	 fatty	 acid	 oxidation.	 Thus,	
overexpression	of	PPARδ in	muscle	 increases	 the	oxidative	capacity	 in	a	very	marked	
way.	In	fact,	mice	that	express	large	amounts	of	PPARδ	in	muscle	(marathon	mice)	can	
run	for	hours	without	stopping	(Y.	X.	Wang	et	al.	2004).				
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However,	 in	 liver,	 PPARδ plays	 a	 lipogenic	 role	 as	 indicated	 by	 overexpression	
(adenovirus)	experiments	(S.	Liu	et	al.	2011)	or	knockout	animal	models(C.-H.	Lee	et	al.	
2006).	Recently,	it	has	been	shown	that	PPARδ	controls	diurnal	expression	of	lipogenic	
genes	 in	 the	 dark/feeding	 cycle	 (S.	 Liu	 et	 al.	 2013).	 Liver-specific	 PPARδ	 activation	
increases,	whereas	hepatocyte	PPARδ	deletion	reduces,	muscle	fatty	acid	uptake.		An	
unbiased	metabolite	profiling	identified	the	phospholipid	1-oleico-2-oleoyl-sn-glycerol-
3-phosphocholine	(18:0/18:1	GPC)	as	a	serum	lipid	regulated	by	diurnal	hepatic	PPARδ	
activity.	 Interestingly,	 18:0/18:1-GPC	 reduces	 postprandial	 lipid	 levels	 and	 increases	
fatty	acid	use	through	muscle	PPARα	(S.	Liu	et	al.	2013).		
	
PPARδ	expression	 peaks	 at	 night	 parallel	 to	 the	mRNA	 levels	 of	 the	molecular	 clock	
Bmal1	in	the	liver.	Therefore,	it	is	feasible	that	hepatic	PPARδ  alters	the	expression	of	
muscle	 genes	 and	 FA	 use	 through	 PC	 (18:0/18:1),	 indicating	 that	 an	 hepatic	 PPARδ-
PC(18:0/18:1)-muscle	PPARα signalling	cascade	coordinates	fat	synthesis	and	use.	
	
That	 PPARα	 ligands	 are	 products	 of	 the	 de	 novo	 synthesis	 of	 FA	 illustrates	 a	 link	
between	hepatic	lipogenesis	and	peripheral	FAO.	This	link	can	explain	how	tissues	like	
muscle	oxidize	fatty	acids,	depending	on	circadian	hepatic	synthesis,	at	specific	times	
coinciding	 to	 the	animal	activity.	However,	as	mentioned	before,	 the	 requirement	of	
de	 novo	 synthesis	 to	 activate	 FAO	 presents	 a	 significant	 problem	 during	 the	 fasting	
state,	where	PPAR	in	liver	becomes	active	to	promote	FAO	and	ketogenesis,	but	there	
is	not	any	endogenous	ligand	supply	available	by	diet	or	de	novo	synthesis.	
	
During	 periods	 of	 fasting,	 the	 liver	 needs	 to	 adapt	 its	 metabolism	 to	 maintain	 the	
production	 of	 glucose	 and	 keep	 a	 state	 of	 normoglycemia.	 Gluconeogenesis	 takes	
action	when	the	reducing	power	(NADH)	is	made	available	through	the	mitochondrial	
oxidation	of	FAs	mobilized	 from	WAT	during	 fasting	 (McGarry	and	Foster	1995).	The	
liver	synthesizes	ketone	bodies,	which	are	soluble	products	of	incomplete	oxidation	of	
FAs	 that,	 in	 addition	 to	 replace	glucose	as	 an	energy	 source,	 increases	 the	 FAO	 rate	
(Vilà-Brau	et	al.	2011b).	As	proposed	by	Denis	McGarry	 in	1980	(McGarry	and	Foster	
1995)	a	powerful	oxidation	of	fatty	acids	 is	needed	to	maintain	normoglycemia	(Vilà-
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Brau	 et	 al.	 2013).	More	 relevant,	 ketogenesis	 is	 needed	 to	maintain	 the	β-oxidation	
flux	of	fatty	acids,	probably	because	releases	free	CoA	from	the	acyl-CoA	allowing	the	
activation	 of	 new	 acyl	 molecules.	 In	 agreement,	 Hmgcs2,	 the	 gene	 that	 controls	
ketogenesis	 (Ayté	 et	 al.	 1990),	 is	 involved	 in	 the	 induction	 of	 fatty	 acid	 oxidation	
mediated	by	PPARα	in	HepG2	cell	line(Vilà-Brau	et	al.	2011b).	Thus,	the	expression	of	a	
specific	shRNA	in	liver	of	fasted	animals,	that	reduced	hepatic	Hmgcs2	activity	by	50%,	
correlated	with	a	20%	decrease	in	liver	FAO(Vilà-Brau	et	al.	2013).		
	
Seeking	 for	 new	 mechanisms	 involved	 in	 liver	 gene	 expression	 during	 starvation,	 a	
microarray	 was	 performed	 to	 compare	 the	 expression	 pattern	 of	 wild	 type	 with	
HMGCS2	 knockdown	 animals.	 One	 of	 the	 genes	 that	 was	 up	 regulated	 when	
ketogenesis,	 and	 therefore	 FAO,	 was	 blocked	 was	 Fsp27β/CIDEC.	 Similar	 result	 was	
obtained	 when	 a	 pharmacological	 inhibition	 of	 CPT1A	 was	 used	 to	 blunt	 FAO	 in	
liver(Vilà-Brau	et	al.	2013).	
	
Fsp27β	(formerly	referred	as	Fsp27)	shows	a	peculiar	pattern	of	expression	during	liver	
adaptation	to	fasting	(Figure	R1).	Thus,	is	highly	expressed	in	the	early	period	(6	h)	of	
fasting	 but	 over	 longer	 periods	 of	 fasting	 (15-24	 h),	 the	 expression	 of	 Fsp27β	
decreases.	 FSP27	 is	 as	 a	 lipid-droplet	 formation	 protein,	 and	 its	 induction	 during	
fasting	was	unexpected.	Nonetheless,	in	humans	more	than	60%	of	the	FAs	that	reach	
the	liver	during	fasting	are	re-esterified	(Kalhan	et	al.	2001)	and	a	futile	cycle	of	TG/FA	
has	 been	 proposed	 in	 fasting	 (Hanson	 and	 Reshef	 2003).	 Interestingly,	 FSP27β	 was	
shown	to	be	a	direct	mediator	of	PPARγ-dependent	hepatic	steatosis(Yu	et	al.	2003),	
and	that	forced	expression	of	recombinant	tagged-FSP27α	in	hepatocytes	significantly	
decreases	mitochondrial	β-oxidation	(Matsusue	et	al.	2008).	This	observation	suggests	
that	expression	of	FSP27β may	promote	LD	formation	in	hepatocytes.	The	LDs	created	
will	transitorily	accommodate,	not	only	the	flood	of	fatty	acids	coming	from	WAT,	but	
also	 the	 endogenous	 phospholipids	 needed	 for	 the	 LDs	 generation.	 In	 concordance,	
Fsp27β	expression	drops	when	PPARα	target	genes	are	robustly	expressed	(>	15	h	of	
fasting)	 and	 FAO	 is	 rate	 is	 maxim	 (Puri	 et	 al.	 2007).	 Hence,	 we	 hypothesize	 that	
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FSP27β,	in	addition	to	participate	in	the	accumulation/export	of	the	newly	synthesized	
TGs	may	also	be	involved	in	PPARα	signaling	in	the	steps	of	adaptation	to	fasting.	
	
	
From	this	point,	two	main	objectives	were	set	to	understand:		
	
1)	 If	 the	 peculiar	 pattern	 of	 Fsp27β	 expression	 in	 liver	 plays	 a	 role	 in	 PPARα	
signaling	by	accumulating/liberating	specific	endogenous	ligands.	
2)	 The	 transcriptional	mechanisms	 responsible	 for	 the	 drop	 of	 Fsp27β	 expression	
during	late	fasting.		
	
The	discovery	of	two	forms	of	FSP27	(α	and	β)	(Xu	et	al.	2015)	did	not	change	our	first	
objective	 since	 FSP27β	 is	 the	 main	 form	 expressed	 in	 liver	 (Figure	 1	 and	 (Xu	 et	 al.	
2015)).	However,	it	affects	our	strategy	of	studying	the	role	of	FSP27β	in	liver.	A	floxed	
mouse	line	was	generated	in	which	the	first	loxP	site	was	introduced	in	the	first	intron	
of	 the	 Fsp27	 gene	 (Tanaka	 et	 al.	 2015),	 before	 discovering	 that	 Fsp27	 gene	 has	 an	
alternative	promoter	that	drives	the	expression	of	β	isoform	(Xu	et	al.	2015).	Sequence	
of	the	floxed	allele	(A.	Baldan,	personal	communication)	shows	that	the	loxP	sequence	
disturbed	 the	 CREBH	 element,	 present	 upstream	 of	 exon	 1B,	 that	 is	 essential	 for	 it	
expression	(Figures	6-8	and	(Xu	et	al.	2015)),	therefore	this	animal	has	down	regulated	
the	 CREBH-dependent	 Fsp27β	 expression	 in	 all	 tissues	 and	 was	 discarded	 for	 this	
study.	
	
Therefore,	 we	 decided	 to	 use	 adenovirus-mediated	 interference,	 to	 acute	 down	
regulate	Fsp27β	expression	 in	 liver	of	fasted	animals,	and	study	the	effect	of	 iRNA	in	
TAG	 and	 GPC	 (18:0/18:1,	 and	 16:0/18:1)	 levels	 in	 liver	 and	 serum.	 In	 addition,	 we	
studied	in	this	experimental	model,	the	expression	pattern	of	bona	fide	PPARα target	
genes	in	liver,	WAT,	BAT	and	muscle.	
	
Our	data	indicates	that	while	Fsp27β	does	not	appear	to	have	an	impact	in	total	TAG	in	
the	serum	of	starved	animals	(Figure	R	17A),	however,	 it	appears	critical	for	the	liver	
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steatosis	 induced	 by	 fasting	 (Figure	 R	 17B).	 Importantly,	 liver	 Fsp27β	 expression	
appears	also	important	for	TAG	accumulation	in	liver	under	feeding	conditions	(Figure	
R	17B).	Fasting	reduces	the	analyzed	GPC	in	serum,	but	in	the	animals	lacking	hepatic	
Fsp27β,	 the	 phospholipids	 in	 serum	 are	 higher	 (Figure	 R	 18).	 Therefore,	 despite	 the	
role	of	Fsp27β	 in	 liver	 lipid	droplet	 formation,	 this	 result	 encouraged	 the	analysis	of	
PPARα-target	 gene	expression	 in	 liver	and	extrahepatic	 tissues,	 since	 it	 appears	 that	
PPARα	ligands	are	overflowing	in	a	liver	that	lacks	Fsp27β	expression.	It	is	important	to	
note	that	in	untreated	animals,	fasting	induces	serum	TAG	(Figure	R	17A)	but	reduced	
serum	phospholipids	 (Figure	R	17B),	 that	 is	probable	 related	with	 the	precedence	of	
TAG	(WAT)	and	phospholipids	(liver).	
	
Overflow	of	PPARα	ligands	from	liver	correlates	with	lower	expression	of	PPARα-target	
genes	 (Figure	 R	 16).	 However,	 not	 all	 transcripts	 characterized	 as	 PPARα	 target	
respond	in	the	liver	to	Fsp27β	knock	down.	In	fact,	the	loss	of	Fsp27β	induction	during	
fasting	(Figure	R	15)	appears	to	affect	mostly	genes	that	show	a	late	induction	during	
fasting,	like	Fgf21	(Figure	R	16A)(Estall	et	al.	2009)	or	Hmgcs2	(Figure	R	16B)	(Vilà-Brau	
et	al.	2013),	rather	than	early	responsive	genes	like	Cpt2	(Figure	R	16	C)(Vilà-Brau	et	al.	
2013).	 This	 observation	 reinforces	 our	 proposed	 model	 for	 PPARα	 signaling	 during	
fasting.	 In	addition,	no	effect	was	observed	 in	a	muscle	PPARα	 target	gene	(Figure	R	
19F),	suggesting	that	 further	signals	are	necessary	for	the	expression	of	those	genes,	
which	are	not	present	during	nutrient	sparseness.	
	
The	role	of	PPARα	signaling	in	BAT	is	quite	intriguing	since	down-regulation	of	Fsp27β	
in	liver	avoids	the	hepatic	steatosis	(Figure	R	17B)	without	any	stimulation	of	liver	FAO	
(Figure	R	16	and	(Langhi	and	Baldán	2014))	nor	serum	TAG	(Figure	R	17A	and	(Langhi	
and	Baldán	2014)).	 The	 induction	of	Fsp27β	 in	BAT	 (Figure	R	17E)	 indicates	 that	our	
adenovirus	 specifically	 targets	 the	 liver	 of	 treated	 animals	 and	 hits	 inside	 the	 open	
debate	about	 if	Fsp27	 is	a	PPARα	 target	gene.	Others	(Matsusue	et	al.	2008)	and	we	
(Vilà-Brau	et	al.	2013)	have	indicated	that	liver	expression	of	Fsp27β	is	not	dependent	
of	 PPARα	 signaling.	 However,	 Baldan	 group	 had	 shown	 that	 Fsp27β	 expression	 is	
stimulated	by	pharmacological	activation	of	PPARα	(Langhi	and	Baldán	2014),	despite	
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no	 induction	by	 fasting	was	observed	 in	a	PPARα knock	out	mice	(Langhi	and	Baldán	
2014).	The	 result	 shown	here	 (Figure	R	17E)	could	somehow	conciliate	contradictory	
data,	since	appears	that	Fsp27β	could	be	a	target	of	PPARα	in	extrahepatic	tissues.		
	
As	 so,	 the	 induction	 of	 PPARα	 signaling	 in	 BAT,	 during	 lack	 of	 hepatic	 Fsp27β	
expression,	 uncovered	 an	 adaptative	 mechanism	 in	 which	 the	 fatty	 acids	 obtained	
from	diet	or	the	liver	de	novo	synthesis	will	regulate	FAO	in	extra-hepatic	tissues.	
	
The	report	of	the	β	form	(Xu	et	al.	2015)	generated	from	an	alternative	promoter		has	
an	 obviously	 impact	 regarding	 our	 second	 of	 our	 objective	 in	 this	 Thesis,	 the	
mechanism	 that	 controls	 Fsp27β	 expression	 during	 early	 and	 late	 fasting.	 In	 the	
putative	 role	 of	 the	 Fsp27β	 on	 PPARa	 signaling	 could	 be	 important	 the	 induction	
during	 the	 early	 fasting,	 but	 also	 the	 down-regulation	 observed	 during	 late	 fasting	
(Figure	R	2	and(Vilà-Brau	et	al.	2013)).		
	
The	gene	transcription	program	during	the	 liver-fasting	adaptation	can	be	divide	 into	
two	 temporally	 phases	 separated	 by	 the	 status	 of	 SIRT1	 activation	 (Dominy	 et	 al.	
2010).	With	 sustained	 fasting	 (>12–18	h),	 SIRT1	becomes	activated	and	deacetylates	
proteins	like	CRTC2	(Y.	Liu	et	al.	2009)	or	CREBH(Hyunbae	Kim	et	al.	2015c).	This	event	
allows	 the	 ubiquitination	 of	 the	 protein	 and	 subsequent	 degradation	 (Y.	 Liu	 et	 al.	
2009).	Fsp27β	expression	was	induced	in	the	liver	of	SIRT1	KO	animal	(Vilà-Brau	et	al.	
2013),	and	originally	a	role	for	CRTC2	was	proposed	in	the	early	expression	of	FSP27,	
suggesting	that	CRTC2	degradation	could	be	involved	in	Fsp27	down	regulation	during	
late	fasting	(Vilà-Brau	et	al.	2013).	Nonetheless,	we	now	know	that	the	liver	expresses	
only	 the	 beta	 form	 of	 FSP27,	 through	 a	 mechanism	 that	 involves	 CREBH	 (Xu	 et	 al.	
2015).	Thus,	a	more	plausible	pathway	is	that	deacetylation	events	mediated	by	SIRT1	
attenuate	CREBH	activity	(Hyunbae	Kim	et	al.	2015c)	and	diminish	Fsp27β	expression	
during	late	fasting.		
	
In	 fact,	we	 show	herein	 that	 expression	 (Figure	3A)	 and	acetylation	 status	of	CREBH	
(Figure	 7)	 is	 important	 for	 its	 transcriptional	 activity	 on	 the	 Fsp27β	 promoter.	
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However,	the	exact	mechanism	is	still	elusive	since	PPARα	appears	not	to	be	involved	
in	Fsp27β liver	expression	(Figure	6	and(Vilà-Brau	et	al.	2013;	Matsusue	et	al.	2008)).	
	
Other	 possible	 mechanism	 for	 the	 down	 regulation	 of	 Fsp27β	 is	 the	 existence	 of	 a	
repressor	 expressed	 and/or	 activated	 during	 long	 fasting	 period.	 We	 studied	 the	
putative	role	of	REV-ERBα	and	HNF6	since	deletion	of	each	of	those	genes	generates	
animal	 models	 with	 hepatic	 steatosis	 (Y.	 Zhang	 et	 al.	 2016b).	 In	 addition,	 the	
expression	 pattern	 of	 REV-ERBα	 was	 compatible	 with	 this	 role	 (Figure	 R	 3B),	 and	 a	
putative	binding	site	of	Rev-Erbα	has	been	described	in	the	5´	flanking	region	of	mouse	
Fsp27	 gene	 by	 Chromatin	 Immunoprecipitation	 analysis.	 Lack	 of	 response	 of	 the	
cloned	promoter	to	ROR	and	REV-ERBα	(Figure	R	9)	was	probably	due	to	the	length	of	
the	cloned	promoter	(Figure	R	5).	Please	note	that	ChIp	analysis	were	performed	with	
wild	type	and	DBD	mutant	proteins.	REV-ERBα	can	repress	gene	expression	in	a	tissue	
specific	way	by	interacting	with	tissue	specific	factors	like	HNF6	(Y.	Zhang	et	al.	2016b).	
In	 our	 hands,	 HNF6	 was	 capable	 to	 reduce	 reporter	 assay	 activities,	 but	 promoter-
deletion	 experiments	 shows	 that	 this	 effect	map	 in	 the	 CREBH	 responsive	 element,	
suggesting	a	non-physiologic	squelching	phenomena	(Figure	R	12).	
	
That	 PPARα	 ligands	 are	 products	 of	 the	 de	 novo	 synthesis	 of	 FA	 provides	 a	 link	
between	hepatic	lipogenesis	and	peripheral	FAO.	This	link	can	explain	how	tissues	like	
muscle	oxidize	fatty	acids,	depending	on	circadian	hepatic	synthesis	(S.	Liu	et	al.	2013),	
at	 specific	 times	 coinciding	 to	 the	 animal	 activity.	 However,	 the	 requirement	 of	 de	
novo	synthesis	to	activate	FAO	presents	a	significant	problem	during	the	fasting	state,	
where	PPARα	in	liver	becomes	active	to	promote	FAO	and	ketogenesis	(Kersten	et	al.	
1999),	 but	 there	 is	 not	 any	 endogenous	 ligand	 supply	 available	 by	 diet	 or	 de	 novo	
synthesis.	In	HepG2	cells,	the	forced	expression	of	FSP27α,	blunts	the	PPARα	response	
when	 measured	 by	 using	 a	 PPRE-TK	 reporter	 (Figure	 R	 14).	 The	 response	 of	 the	
luciferase	 can	be	 rescued,	 in	 the	presence	of	 FSP27α,	 by	 using	 a	 synthetic	 ligand	of	
PPARα.	That	the	synthetic	ligand	did	not	have	an	effect	in	the	absence	of	PPARα	was	
attributed	to	the	presence	of	endogenous	ligands	that,	after	all,	make	the	assay	works.	
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The	peculiar	 expression	pattern	of	Fsp27β	 during	 fasting	 (Vilà-Brau	et	 al.	 2013)	may	
explain	 at	 least	 in	 part	 this	 paradox.	 The	 liver	 of	 a	 fasted	 animal	 becomes	 steatotic	
during	 fasting	 because	 of	 the	 fatty	 acids	 (NEFA)	 coming	 from	white	 adipose	 tissue,	
where	lipolysis	is	stimulated.	In	the	liver,	these	fatty	acids	can	serve	as	fuel	to	produce	
ATP	 and	 reducing	 power	 necessary	 for	 gluconeogenesis(McGarry	 and	 Foster	 1995).	
The	 fatty	acids	 liberated	 from	the	adipose	 tissue	are	not	 capable	 to	activate	PPARα,	
but	could	increase,	via	CREBH,	Fsp27β	expression	(Xu	et	al.	2015;	Jaeger	et	al.	2015),	
thus	promoting	the	generation	of	LDs.	The	LDs	created	will	transitorily	accommodate,	
not	 only	 the	 flood	 of	 fatty	 acids	 coming	 from	 WAT,	 but	 also	 the	 endogenous	
phospholipids,	needed	for	the	LDs	generation.	
	
Therefore,	we	speculate	that	in	liver	during	the	early	fasting,	Fsp27β	expression	allows	
trapping	of	endogenous	newly	synthetized	PPARα	 ligands,	which	in	fed	condition	will	
be	acting	as	PPARα	activators	in	extra	hepatic	tissues.	During	late	fasting,	physiologic	
down	regulation	of	Fsp27β	will	allow	PPARa	activation	characteristic	of	the	fasted	liver.	
According	 with	 this	 hypothesis,	 when	 we	 turn	 down	 liver	 Fsp27β	 expression,	 the	
serum	 of	 these	 animals	 carries	 higher	 concentration	 of	 PPARα	 endogenous	 ligands	
(Figure	R	18B).	This	effect	correlates	with	a	higher	expression	of	PPARα	target	genes	in	
BAT	(Figure	R	19	A-E)	and	lower	in	liver	(Figure	R	16).	
	
In	summary,	our	model	proposes	that	during	early	fasting	fatty	acids	delivered	by	WAT	
will	 induce,	 through	 CREBH-FSP27β	 axis,	 the	 formation	 of	 LDs	 in	 liver,	 which	 are	
needed	 to	 produce	 a	 transitory	 steatosis	 and,	 in	 addition,	 avoid	 the	 release	 of	
endogenous	 PPARα	 ligands	 from	 the	 liver.	 Conversely,	 during	 the	 late	 fasting,	 SIRT1	
activity,	 also	 through	 CREBH	modulation	 (Figure	 R	 7),	 will	 mediate	 FSP27	 clearance	
from	a	liver	that	is	already	prepared	to	oxidize	fatty	acids.	In	turn,	the	increased	FAO	
capacity	 from	 liver	 could	alleviated	ER	 stress	 contributing	 to	CREBH	downregulation.	
During	fed	states,	the	absence	of	Fsp27β	in	liver	will	allow	the	new	synthetized	fat	to	
leave	 the	 liver	 and	 actuate	 as	 PPARα	 agonist	 in	 extrahepatic	 tissues	 like	 BAT.	 Our	
working	hypothesis	is	summarized	in	scheme	I.	
DISCUSSION	
	82	
	
Scheme	I.-	putative	role	of	FSP27β 	during	the	transition	od	early	to	late	fasting	in	liver.	Early	response	(CREBH)	
will	allow	accumulation	of	NEFA	and	PGC.	Late	downregulation	(SIRT1)	will	be	concomitant	to	strong	FAO.	
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FSP27	isoform	expression	
	
	
Fsp27β	is	the	main	isoform	expressed	in	tissues	that	actively	oxidize	fatty	acids	such	as	
liver	 and	 BAT.	 However,	 its	 function	must	 be	 broader	 because	 its	 expression	 is	 also	
predominant,	with	respect	to	Fsp27α,	in	the	small	intestine.	
The	expression	of	Fsp27β	fluctuates	in	the	liver	during	fasting:	it	increases	during	the	
early	 fasting	 (<12h)	 but	 decreases	 during	 the	 late	 fasting	 (>	 12h),	 according	 with	 a	
more	complex	function	than	the	simple	accumulation	of	NEFAs,	coming	from	the	WAT,	
prior	to	their	oxidation.	
	
	
FSP27β 	Transcriptional	regulation	
	
	
Fsp27β	 is	a	 target	gene	of	CREBH,	but	not	of	PPARα.	There	 is	no	cross	 talk	between	
both	transcription	factors	in	the	hepatic	expression	of	Fsp27β.	
Fsp27β	 expression	 depends	 on	 the	 level	 of	 acetylation	 of	 CREBH.	 This	 data	 could		
explain,	 at	 least	 in	 part,	 the	 expression	 pattern	 of	 Fsp27β	 during	 prolonged	 fasting	
where	the	acetylation	state	of	CREBH	diminishes.		
	
	
FSP27β 	Function	
	
	
FSP27β	expression	is	necessary	for	the	hepatic	accumulation	of	TAG	in	liver	and	plays	a	
fundamental	role	in	the	development	of	the	physiological	hepatic	steatosis	that	occurs	
during	fasting	during.		
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The	hepatic	expression	of	FSP27β is	necessary	for	the	correct	signaling	of	PPARa	during	
fasting	 at	 least	 in	 part	 because	 FSP27β	 plays	 a	 key	 role	 in	 the	 storage/release	 of	
phospholipids	proposed	as	endogenous	ligands	of	PPARa	form	the	liver	lipid	droplets.		
In	vitro,	Fsp27β	interferes	with	the	PPARα	signaling	as	it	was	determined	by	the	use	of	
a	TK-luciferase	reporter	under	the	control	of	three	PPRE.	
	
Lack	of	Fsp27β	expression	Increases	the	concentration	of	PPARα	endogenous	 ligands	
in	serum,	which	triggers	the	PPARα	signaling	of	in	peripheral	tissues	such	as	BAT,	while	
decreasing	 its	 signaling	 in	 the	 liver.	 Concretely,	 Fsp27β	 plays	 a	 role	 in	 the	 down-
regulation	of	PPARα	target	genes	in	BAT	during	fasting.																																	
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A	
AcOH	
Acetic	Acid		
AML12	
Alpha	Mouse	Liver	12		
B	
BAT	
Brown	Adipose	Tissue		
C	
CE	
Collision	Energy	
CHCl3	
Chloroform	
CHO	
Carbohydrate	
CHRE	
CREBH	Response	Elements		
CMV	
Citomegalovirus	
Cpt1b	
Carnitine	palmitoyltransferase	I		
Cpt2	
Carnitine	palmitoyltransferase	2	
CRE	
CREB	Response	Elements		
CREB	
Creb-Responsive	Element	Binding	Protein	
CREBH	
cyclic-AMP-responsive	element	binding	protein	H		
CsCl	
Caesium	Chloride	
Ct	
Threshold	Cycle		
CXP	
Colision	Cell	Exit	Potential	
D	
DEPC	
Diethylpyrocarbonate		
DMEM	
Dulbecco's	Modified	Eagle	Medium	
DMEM:F12	
Dulbecco's	Modified	Eagle	Medium	and	Ham's	F12	medium	
DNA	
Deoxyribonucleic	Acid		
dNTPs	
Deoxyribonucleotide	Triphosphate	
DP	
Declustering	Potential	
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F	
FBS	
Fetal	Bovine	Serum	
FoxA2	
Forkhead	box	A2		
FoxO3a	
Forkhead	box	O3a		
FSP27	
Fat-Specific	Protein	27		
Fsp27α:Fat-Specific	Protein	alpha		
Fsp27β:Fat-Specific	Protein	beta	
G	
GFP	
Green	Fluorescence	Protein	
H	
H2O	
Water	
HEK-293	
Human	Embryonic	Kidney	
HFD	
High-Fat	Diet		
Hmgcs2	
3-hydroxy-3-methylglutaryl-CoA	synthase	2	
HNF6	
Hepatocyte	Nuclear	Factor	6		
HPLC	
High-Performance	Liquid	Chromatography		
L	
LC-MS	
Liquid	Chromatography	-	Mass	Spectroscopy	·	23	
M	
MEM	
Eagle's	Minimum	Essential	Medium	·	11,	12	
MeOH	
Methanol	·	22,	23	
MRM	
Multiple	Reaction	Monitoring	·	23	
mRNA	
messeger	RNA	·	25,	65,	66	
MS/MS	
Mass	spectrometry	·	23	
MTBE	
Methyl-tert-butyl-ether	·	22	
P	
PBS	
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Phosphate	Buffer	Solution		
PC	
Pyruvate	Carboxylase		
PCAF	
P300/CBP-associated	factor	
PCR	
Polymerase	Chain	Reaction		
PPAR	
Peroxisome	Proliferator-Activated	Receptor		
PPRE	
Peroxisome	Proliferaor	Responsive	Element	
Peroxisome	Proliferator	Responsive	Element	
Prot	
Protein	
Q	
qPCR	
quantitative	real	time	Polymerase	Chain	Reaction	
R	
RNA	
Ribonucleic	Acid		
RORa:Retinoid-related	orphan	receptor	alpha		
S	
SEM	
Standard	Error	of	the	Mean		
shRNA	
short	hairpin	RNA	
SIRT1	
Sirtuin	1		
T	
TAG	
Triglycerides		
TGF	
Transforming	Growth	Factor		
TK	
Thymidine-Kinase	
U	
UcpI	
Uncoupling	protein	one		
Z	
ZT	
Zeitgeber	time		
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Scope: Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic candidate
for the treatment of obesity. Since FGF21 production is regulated by various nutritional factors,
we analyze the impact of low protein intake on circulating levels of this growth hormone in
mice and in a sub cohort of the PREDIMED (Prevencio´n con Dieta Mediterra´nea) trial. We also
describe the role of hepatic FGF21 in metabolic adaptation to a low-protein diet (LPD).
Methods and results: We fed control and liver-specific Fgf21 knockout (LFgf21KO) mice a
LPD. This diet increased FGF21 production by inducing its overexpression in liver, and this
correlated with a body weight decrease without changes in food intake. The LPD also caused
FGF21-dependent browning in subcutaneous white adipose tissue (scWAT), as indicated by
an increase in the expression of uncoupling protein 1 (UCP1). In a subgroup of 78 individuals
from the PREDIMED trial, we observed an inverse correlation between protein intake and
circulating FGF21 levels.
Conclusion: Our results reinforce the involvement of FGF21 in coordinating energy home-
ostasis under a range of nutritional conditions. Moreover, here we describe an approach to
increase the endogenous production of FGF21, which if demonstrated functional in humans,
could generate a treatment for obesity.
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1 Introduction
FGF21 (Fibroblast growth factor 21) is considered a promis-
ing therapeutic candidate for the treatment of obesity and
type-2 diabetes. Its administration to obese rodents andmon-
keys leads to decreased plasma concentrations of glucose,
insulin, triglycerides and cholesterol, as well as a reduction
in bodyweight through increased energy expenditure (EE) [1].
The injection of FGF21 in experimental animals induces in-
creased thermogenic capacity by stimulating the expression
of uncoupling protein 1 (UCP1) and type 2 iodothyronine
deiodinase protein 2 (DIO2) in brown adipose tissue (BAT),
and UCP1 in white adipose tissue (WAT), where it produces
the so-called browning process [2,3]. Althoughmost of the ef-
fects of FGF21 have been related to UCP1 expression, it has
also been reported that Ucp1-null mice respond positively
to the pharmacological administration of this growth factor
[4, 5].
FGF21 is a member of the FGF family, which is charac-
terized by endocrine properties. It is produced mainly by the
liver, but also by other tissues such as WAT, BAT, skeletal
muscle, and pancreas [6–9]. Expression of FGF21 in the liver
is induced by fasting, and its transcriptional activity is tightly
controlled by peroxisome proliferator-activated receptor al-
pha (PPAR-) [10–13]. The expression of this growth factor
in liver activates fatty acid oxidation (FAO), ketogenesis, and
gluconeogenesis in this organ, thereby triggering ametabolic
state that mimics long-term fasting [14].
In addition to fasting, FGF21 expression is also induced
in various tissues in response to a number of nutritional chal-
lenges and also to cold exposure. In this regard, FGF21 ex-
pression in BAT is produced in response to cold temperature
[9,15], although it is unclear whether BAT-derived FGF21 acts
as an endocrine factor or whether it is simply an autocrine
factor in the adipose tissue itself.
In mouse liver and HepG2 cells, FGF21 is induced by
leucine-deprivation as part of the transcriptional program
initiated by increased levels of activating transcription fac-
tor 4 (ATF4) [16]. The ATF4-dependent increase in FGF21
expression has been confirmed in mice with autophagy defi-
ciency in skeletal muscle and in liver [17]. Interestingly, these
mice are protected from diet-induced obesity (DIO) and in-
sulin resistance. The similarities in the metabolic responses
between the effects to leucine-deprivation [18] and to FGF21
overexpression allowed us to consider FGF21 as a key media-
tor between amino acid deprivation and lipid metabolism in
liver, WAT, and BAT. In this regard, results from the eval-
uation of the metabolic response of Fgf21-deficient mice to
a leucine-deficient diet previously led us to conclude that, as
expected, most of the effects caused by leucine deprivation
in liver, WAT, and BAT are impaired in the absence of this
growth factor [19].
Likewise, methionine-deprived mice show a phenotype
comparable to that of leucine-deprivation, including resis-
tance to a high-fat diet (HFD), improved glucose homeosta-
sis, increased fatty acid activation and FAO in liver, enhanced
lipolysis in WAT, and increased UCP1 expression in BAT
[20, 21]. Of note, the induction of hepatic FGF21 expression
under leucine- or methionine-restricted diets was found to
be accompanied by an increase in FGF21 protein levels in
serum.
In order to facilitate the translation of these findings to
humans, here we focussed on low-protein diets (LPD) instead
of amino acid-deficient diets. Protein restriction brings about
weight loss and an increase in both food intake and EE [22].
Moreover, a LPD induces thermogenic markers in BAT of
obese rats [23]. Moreover, serum concentrations of FGF21
in both rodents and humans increase upon exposure to an
LPD, regardless of total calorie intake. This observation thus
reveals that FGF21 is likely to be involved in the metabolic
response to protein-restricted diets [24].
Here we addressed whether a LPD exerts similar effects
on lipid metabolism to those of a leucine-deficient diet and
whether these effects are dependent on hepatic FGF21 pro-
duction. To this end, we examined the metabolic response of
wild-type and Fgf21 liver-specific knockout mice (LFgf21KO)
to a LPD (up to 5%of energy as protein). Adecreased indietary
protein content induced a huge increase in FGF21 serum
levels, significant weight loss, and an increase in the expres-
sion of UCP1 in the subcutaneousWAT (scWAT) of wild-type
mice. Remarkably, no effects were observed in Fgf21-deficient
mice, thereby indicating that the absence of FGF21 blunts or
completely blocks the response to a LPD in thismousemodel.
To corroborate these results in humans, we evaluated
whether protein intake is associated with circulating levels
of FGF21. We calculated protein intake through nutritional
questionnaires and determined the serum levels of FGF21
in 78 individuals randomly selected from two nodes of the
PREDIMED (Prevencio´n con Dieta Mediterra´nea) trial. As with
the animal model, an inverse correlation between circulating
FGF21 levels and protein intake was observed.
To summarize, here we define themolecularmechanisms
by which a LPD exerts itsmetabolic effects through the induc-
tion of hepatic FGF21 expression and browning of scWAT.
Furthermore, the data collected from humans raises the pos-
sibility of investigate the dietarymodulation of circulating lev-
els of FGF21 as an alternative approach to its pharmacological
administration. In this regard, we propose the modification
of protein intake to enhance FGF21 production.
2 Material and methods
2.1 Animals
To generate the LFgf21KO mice, Fgf21loxP mice
(Fgf21tm1.2Djm/J) that have Fgf21 flanked by two loxP
sites (Jackson Laboratory, USA) were crossed with Albumin-
cre (Tg(Alb1-cre)1Dlr/J) mice (kindly provided by Dr. A.
Zorzano). The latter express the CRE recombinase enzyme
under control of albumin promoter/enhancer elements,
thus allowing liver-specific gene deletions [25]. Fgf21LoxP
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mice were used as controls. Animals were housed in a
temperature-controlled room (22 ± 1C) on a 12/12 h
light/dark cycle and were provided free access to commercial
rodent chow and tap water prior to the experiments.
2.1.1 Dietary intervention
The control diet (CD) (Ref. D10001) and LPD (Ref.
D12010401) were obtained from Research Diets, Inc. (USA).
Both diets were isocaloric. They had the following composi-
tion (in percentage ofmass): 20% protein, 66% carbohydrates
and 5% fat for the CD, and 5% protein, 81% carbohydrates
and 5% fat for the LPD (detailed composition shown in Sup-
porting Information Table 1). For the feeding experiment,
8-week-old male mice were first fed the CD for 7 days and
then randomly assigned to either the CD or LPD group with
free access to food and water for 7 days. Food intake and body
weight were recorded daily. Animals were then anesthetized
by isoflurane inhalation, and blood was collected by cardiac
puncture. After euthanizing the animals, tissues were iso-
lated and immediately snap-frozen and stored at −80C for
future analysis. The Animal Ethics Committee of the Univer-
sity of Barcelona approved these experiments (CEEA register:
48/15)
2.1.2 Human samples for plasma measurements
Weused plasma samples from 78men and women randomly
selected from the participants of the centers inHospital Clinic
(Barcelona) and Reus (Tarragona) of the PREDIMED trial
(www.predimed.es). This study was a 5-year randomized clin-
ical trial to compare the effects of either a Mediterranean diet
supplemented with extra virgin olive oil or nuts versus a low-
fat control diet. A total of 7447 asymptomatic men but at high
cardiovascular risk (aged 55–80 years) and women (aged 60–
80 years) were recruited. All participants had type 2 diabetes
or three or more cardiovascular risk factors. Details of the
recruitment method and study design have been described
elsewhere [26] and are also available at www.predimed.es. In
addition to the plasma samples, we also gathered informa-
tion from these 78 individuals, including a 137-item semi-
quantitative food frequency questionnaire (FFQ), and a gen-
eral questionnaire that provided data on lifestyle habits, con-
current diseases, anthropometry, and medication use. Total
energy intake and nutrient intake were calculated on the basis
of Spanish food composition tables [27]. The study protocol
was approved by the institutional review boards of the partic-
ipating centers (ISRCTN35739639).
2.1.3 Plasma measurements
Mouse plasma samples were obtained by centrifuging whole
blood collected in EDTA-treated tube. The plasma was stored
at−80C. FGF21 inmouse and human plasmawasmeasured
by means of a Human (ref. EZHFGF21-19K) and Mouse/Rat
(ref. EZRMFGF21-26K) FGF21 ELISA obtained from EMD
Millipore (Germany). The assay was conducted following the
manufacturer’s protocol. Briefly, a calibration curve was con-
structed by plotting the difference in absorbance values at 450
and 590 nm versus the FGF21 concentrations of the calibra-
tors, and concentrations of unknown samples (performed in
duplicate) were determined using this calibration curve. Free
fatty acids (non-esterified fatty acids, NEFA) were determined
in mice plasma by an enzymatic colorimetric assay. The Free
fatty acids, Half-micro test (ref. 11383175001) was obtained
from Sigma-Aldrich (USA). The measure was performed ac-
cording to the manufacturers’ instructions.
2.1.4 RNA isolation and relative quantitative RT-PCR
Total RNA was extracted from the frozen tissues [liver, epi-
didymal WAT (eWAT), BAT and inguinal scWAT] using TRI
reagent solution (ref. AM9738 Ambion, Thermo Fisher Sci-
entific, USA) followed by DNase I treatment (ref. AM1906,
Ambion, Thermo Fisher Scientific, USA) to eliminate ge-
nomic DNA contamination. To measure the relative mRNA
levels, quantitative (q)RT-PCR was performed using SYBR
Green or TaqMan reagents. cDNA was synthesized from 1
g of total RNA by MLV reverse transcriptase (ref. 28025021,
Invitrogen, ThermoFisher Scientific, USA)with randomhex-
amers (ref. 11034731001, Roche Diagnostics, Germany), fol-
lowing the manufacturer’s instructions. The TaqMan Gene
ExpressionMasterMix (ref. 4369514) and SYBR R© GreenPCR
Master Mix (ref. 4364344), supplied by Applied Biosystems
(ThermoFisher Scientific, USA), were used for the PCR step.
Amplification and detection were performed using the Step-
One Plus Real-Time PCR System (Applied Biosystems, Ther-
moFisher Scientific, USA). EachmRNA from a single sample
was measured in duplicate, using 18S, Beta-Actin, and 36b4
as housekeeping genes. The primer sequences are shown in
Supporting Information Table 2. Results were obtained by
the Relative Standard Curve Method and expressed as fold
increase versus the experimental control.
2.1.5 Protein extracts preparation
To obtain liver nuclear extracts, frozen liver was triturated
with a mortar in liquid nitrogen and immediately homoge-
nized with a Dounce in 1 mL of HB buffer [15 mM Tris-HCl
(pH 8), 15 mM NaCl, 60 mM KCl, 0.5 mM EDTA], and cen-
trifuged at 800 × g for 5 min. The resulting pellet was re-
suspended in 100 L of HB buffer supplemented with 0.05%
TritonX-100 (Sigma,USA) and centrifuged for 10min at 1000
× g. Nuclear pellets were washed with 1mL ofHB buffer sup-
plemented with 0.05% Triton X-100 and 1 mL of HB buffer.
Nuclei were incubated at 4C for 30 min in 50 L of HB
buffer containing 360 mM of KCl and then centrifuged for
5 min at 10 000 × g. The supernatants corresponding to the
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 1. FGF21 is induced by an LPD
in liver but not in BAT or WAT, and
this induction correlates positively with
plasma concentration in mice. Plasma
protein concentration of FGF21 was
measured by ELISA (A). Fgf21 mRNA
levels in liver (B) and WAT and BAT (C)
were measured by qRT-PCR. Error bars
represent the mean ± SEM. **p<0.01
***p<0.001 versus Fgf21LoxP mice fed a
CD (n = 7–9/group).
nuclear extracts were collected, frozen, and stored at −80C.
Protein concentrationwas determined using the Bio-Rad Pro-
tein Assay Dye Reagent Concentrate (Ref. 5000006, Bio Rad,
USA). All buffers were supplemented with a mixture of pro-
tease inhibitors (Ref. P8340, Sigma-Aldrich, USA), 0.1 mM
of PMSF, and a phosphatase inhibitor cocktail 3 (Ref. P0044,
Sigma-Aldrich, USA).
2.1.6 Immunoblotting
Nuclear proteins were resolved by SDS-polyacrylamide gel
electrophoresis and transferred onto a Hybond-P PVDF
membrane (Millipore). Membranes were blocked (Tris-HCl
50 mM pH 8, 150 mM, 5% skimmed milk, 0.1% Tween) for
1 h at room temperature. The blots were then incubated with
ATF4 primary antibody (sc-200, Santa Cruz Biotechnology,
Inc., USA) in blocking solution (1:200). After an overnight
incubation at 4C, the blots were washed and incubated with
an anti-rabbit horseradish peroxidase-conjugated secondary
antibody (ref. NA934, Amersham, GE Healthcare, UK) in
blocking buffer for 2 h at room temperature. The blots were
developed using the EZ-ECL Chemiluminescence Detection
Kit for HRP (ref. 20-500-500, Biological Industries, Israel).
Quantification was performed using Image J software.
2.1.7 Data analysis/statistics
For human samples, baseline characteristics are presented
as means ± standard error of the mean (SEM) for contin-
uous variables, frequencies and percentages for categorical
variables across quartiles of protein intake at baseline. Dif-
ferences between quartiles were tested by a 1-factor ANOVA
test for continuous variables and by the chi-square test for
the categorical ones. We performed multiple linear regres-
sions to evaluate the relationship between protein intake
(exposure variable) and FGF21 hormone levels (dependent
variable). Protein intake was previously adjusted for calories
using the residual method. Regression analyses were unad-
justed (model 1) or adjusted by body mass index (BMI) and
total energy intake (model 2).
All statistical analyseswere conductedusingSAS software,
version 9.3 (SAS Institute, Inc., USA). All t tests were two-
sided and p values below 0.05 were considered statistically
significant.
3 Results and discussion
3.1 A LPD induces FGF21 gene expression in the
liver of control mice, but not in BAT or WAT
According to previously reported results, mice on an LPD
show a dramatic increase in serum levels of FGF21 [22–24]
(Fig. 1A). To check the origin of this FGF21, we analyzed
the Fgf21 mRNA levels in several tissues. The liver is the
main site of FGF21 production and release into the blood.
Accordingly, we observed a great induction of Fgf21 mRNA
synthesis in the liver of mice on the LPD (Fig. 1B). This
increase correlated positively with serum levels. In contrast,
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Fgf21 expression was unchanged in BAT, eWAT and scWAT
of control mice (Fgf21loxP) on the same diet (Fig. 1C).
To determine the specific role of hepatic FGF21 in the
metabolic response to a LPD, we fed LFgf21KO mice a LPD
diet. As expected, Fgf21 mRNA levels were undetectable in
the livers of these animals (Fig. 1B), while no statistically
significant changes were detected in BAT, eWAT, or scWAT
when compared to the same tissues in control mice (Fig. 1C).
This mouse model shows that protein restriction almost
exclusively affects the hepatic expression of FGF21 and that
there is no compensatory response in other tissues, such as
BAT or WAT.
We measured the circulating FFA levels as a possible sig-
naling factor for the induction of FGF21 in mice under a low
protein diet. The absence of statistically significant changes
in FFA (data not shown) allow us to rule out the PPAR-FA axis
in the signaling mechanism responsible for the induction of
the hepatic expression of FGF21 in these conditions.
3.2 A LPD increases ATF4 protein levels in mouse
liver
GCN2 is a kinase that acts as a sensor of amino acid sup-
ply [28]. When activated, GCN2 phosphorylates EIF2a, which
results in the slowing or stalling of the initiation step of
mRNA translation. Hence, phospho-EIF2a reduces general
protein synthesis rates. Paradoxically, in these circumstances
there is an increase in the translation of discrete mRNAs,
including ATF4 [29, 30]. A LPD increases GCN2-dependent
phosphorylation of eIF2a, resulting in greater levels of ATF4
protein [31, 32]. ATF4 is a transcriptional factor that directly
or indirectly induces a subset of specific genes to regulate
metabolic adaptation to amino acid restriction. The 5’ region
of Fgf21 contains two evolutionarily conserved functional
ATF4-binding sequences responsible for its ATF4-dependent
transcriptional activation [16, 33]. To determine the effect of
anLPDonATF4 expression,we analyzed liver protein extracts
of mice fed an LPD or a CD for 7 days. ATF4 expression was
induced in liver in response to the LPD, as revealed by West-
ern blot assays (Fig. 2A and B). These results are consistent
with previous published data reporting that ATF4 triggers
the expression of FGF21 and that Gcn2 -/- mice show a par-
tially blunted induction of FGF21 under protein restriction
[24]. On the basis of the aforementioned published data, our
results support the notion that the GCN2-ATF4 pathway is
likely to be the main mechanism underlying hepatic FGF21
overexpression upon protein restriction.
GCN2-independent mechanisms that induce hepatic
FGF21 in response to methionine-restricted diets have re-
cently been described [34]. This observation points to a
different response program in liver via a non-canonical
PERK/nuclear respiratory factor 2 (NRF2) pathway. This al-
ternative pathway could effectively sense and translate the
metabolic responses to methionine restriction in the absence
of GCN2. In parallel, the absence of GCN2 during long-term
Figure 2. An LPD increases ATF4 protein levels in liver. ATF4
protein levels were determined by Western blot analysis using
hepatic nuclear extracts obtained from Fgf21LoxP mice adminis-
tered a CD or LPD (A). The experiment was normalized by actin
protein levels as loading control and the intensity of the bands
were quantified by densitometry with the Image J software (B).
Error bars represent the mean ± SEM. **p<0.01 versus CD (n =
3/group).
dietary protein restriction has been reported to be compen-
sated upstream of ATF4 to induce FGF21 [35]. Globally, the
impact of alternative pathways to stimulate FGF21 expression
under a LPD, whether they involve ATF4 or not, should be
addressed in greater depth.
3.3 Fgf21 deficiency significantly attenuates weight
loss under an LPD
Mice fed an LPD presented rapid weight loss. Here we ad-
dressed whether this phenomenon is dependent on hepatic
FGF21. For this purpose, Fgf21LoxP mice and LFgf21KO mice
were fed a CD or LPD for 7 days.
Our data showed that weight loss was partially blunted
in LFgf21KO mice (Fig. 3A and B). However, the reduction
in food intake observed under an LPD, that can account for
some of the loss in body weight, was unchanged between
genotypes (Fig. 3C). It is remarkable that these results con-
tradicted previous publications describing either no change
or an increase in food intake in response to protein restriction
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 3. Hepatic FGF21 expression is required for the weight loss caused by LPD but does not affect food consumption. Body weight
progression of mice fed a CD or LPD expressed as percentage of the initial weight, which was considered 100% (A). Total body weight
change (g) after 7 days on a CD or LPD (B). Daily food intake (C). Error bars represent the mean ± SEM. **p<0.01 versus Fgf21LoxP mice fed
a CD, #p<0.05 versus LFgf21KO fed a CD; 0.07 represents p value versus LFgf21KO mice fed a CD (n = 7–9/group).
[24]. Nonetheless, the present results are consistent with the
decreased food intake described in mice fed leucine-deficient
diets [19]. Minor changes in diet composition affecting amino
acid bioavailability may explain these discrepancies. More-
over, although FGF21 has the potential to modulate food
preferences [36, 37]. In our mouse model this FGF21 did not
contribute to the food aversion caused by the LPD.
To determine the importance of each tissue in overall
weight loss, we calculated the change in weight of individ-
ual tissues. All tissues analyzed tended to weigh less in mice
on the LPD, reaching statistical significance in heart, liver,
scWAT and p = 0.06 in eWAT (Fig. 4). Regarding the role
of FGF21, our results show that the weight loss observed in
scWAT and heart was dependent on hepatic FGF21 expres-
sion, as weight loss was blunted in LFgf21KOmice under the
same diet. The effect of the LPD on liver tissue weight was
partially abolished by hepatic Fgf21 deficiency (Fig. 4).
Taken together, FGF21 produced by the liver is, at least in
part, responsible for the body weight loss experienced by the
mice on the LPD.Our results point to scWAT as one of the tar-
get tissues of hepatic FGF21 regarding the weight loss effect.
Since hepatic FGF21 exerts its effects mainly in WAT and
BAT through regulating lipid metabolism, the following ex-
periments are focused on describing the role of LPD-induced
FGF21 on the metabolic response of adipose depots.
3.4 LPD induces metabolic changes in response to
FGF21 in scWAT, but not in eWAT or BAT
Thermogenesis in BAT is mediated by the upregulation of
UCP1 [38]. It has been proposed that the induction of FGF21
production by the liver mediates direct activation of brown
fat thermogenesis during the fetal-to-neonatal transition [39].
FGF21 also regulates peroxisome proliferator-activated re-
ceptor gamma coactivator 1-alpha (PGC1a) and browning of
WAT in adaptive thermogenesis [40].
Contrary to what happens under leucine deprivation [19],
no statistically significant induction of Ucp1 or Dio2 mRNA
levels were observed in BAT or eWAT of control mice under
the LPD (Fig. 5A and B). In contrast, the analysis of gene
expression in scWAT revealed that the LPD induced the ex-
pression ofUcp1, Pgc1a, Cidea and PR domain containing 16
(Prdm16), reaching a statistically significant value for Ucp1
and Pgc1a (Fig. 6). This expression pattern was not detected
in the LFgf21KO mice (Fig. 6), thereby indicating the role
Figure 4. Hepatic FGF21 is required for the
weight loss caused by an LPD. The weight
of heart, liver, eWAT, scWAT, BAT, and gas-
trocnemius in mice fed a CD or LPD is
presented as the mg of tissue per 100 mg
of total body weight. Error bars represent
the mean ± SEM. *p<0.05, ***p<0.001
versus Fgf21LoxP mice fed a CD; #p<0.05,
##p<0.01 versus LFgf21KO mice fed a CD;
0.06 represents the p value with respect to
Fgf21LoxP mice fed a CD (n = 7–9/group).
C© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
Mol. Nutr. Food Res. 61, 8, 2017, 1600725 (7 of 10) 1600725
Figure 5. A LPD does not alter thermogenic genes in BAT or
eWAT. Ucp1 and Dio2 expression was measured by qRT-PCR in
mouse BAT and eWAT. Error bars represent the mean ± SEM.
*p<0.05 versus Fgf21LoxP mice fed a CD (n = 7–9/group).
of FGF21 in the metabolic adaptation of scWAT to protein
restriction.
As UCP1 activity is related to EE, the blunted induction
of UCP1 in the LFgf21KO mice under LPD may contribute
to the lower weight loss observed in this mouse model under
these circumstances. In conclusion, hepatic FGF21 induces
the browning of scWAT and increases the thermogenic ca-
pacity of mice on an LPD.
3.5 FGF21 plasma levels correlate negatively with
protein intake in humans
To translate our results to humans, we evaluated the relation-
ship between protein intake and circulating levels of FGF21
in 78 individuals randomly selected from the PREDIMED
trial. Baseline data for these subjects are shown in Table 1.
Protein intake was obtained from FFQs and was expressed
as grams of protein per day (g/day). We used baseline sam-
ples (T = 0). Results from the multiple linear regression
analyses showed a significant inverse relationship between
plasma FGF21 concentrations and dietary intake of protein.
At baseline, FGF21 levels decreased by 3.39 pg/mL for each
gram of protein ingested (Table 2). The participants with a
high intake of protein showed statistically significant lower
values of circulating FGF21.
We also performed regression analyses using quartiles of
protein intake and obtained similar results. After adjustment
for BMI and total energy intake, FGF21 decreased (−30.7
pg/mL) when moving from the lower to higher quartiles (p
= 0.015)(Fig. 7).
Similarly to the data frommice, these results indicate that
the serumconcentrations of FGF21 are inversely proportional
to dietary protein intake.
4 Concluding remarks
Here we addressed the role of hepatic FGF21 in themetabolic
changes triggered by an LPD. Our results demonstrate that
the effects of anLPDdepend, at least in part, on the circulating
levels of FGF21 and consequently on the liver production of
Figure 6. Hepatic FGF21 is required
for inducing thermogenic gene expres-
sion during an LPD. Ucp1, Dio2, Pgc1a,
Pparg, Prmd16, and Cidea expression
was measured by qRT-PCR in mouse
scWAT. Error bars represent the mean
± SEM. *p<0.05 versus Fgf21LoxP mice
fed a CD (n = 7–9/group).
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Table 1. Baseline characteristics of participants from the PREDIMED cohort included in this study, divided into quartiles of energy-adjusted
protein intake at baselinea)
Quartiles of energy-adjusted protein intake p valueb)
Q1 Q2 Q3 Q4
No subjects (78) 19 20 20 19
Age (years) 67.1 ± 5.9 65.7 ± 4.8 67.0 ± 6.4 65.3 ± 4.0 0.30
Sex (women) 6 (31) 10 (50) 9 (45) 15 (79) 0.03
Body mass index (kg/m2) 28.1 ± 3.2 30.0 ± 3.4 27.7 ± 2.7 30.8 ± 2.9 0.006
Energy intake (kcal/day) 2370 ± 350 2192 ± 603 2227 ± 433 2390 ± 571 0.51
Protein intake (g/day) 80 ± 6 90 ± 2 97 ± 3 110 ± 5 <0.0001
FGF21 (pg/mL) 289 ± 116 276 ± 143 256 ± 117 190 ± 115 0.07
a)Categorical variables: subjects (percentage), continuous variables: mean ± SD
b)One-way ANOVA tests (continuous variables) or chi-squared tests (categorical variables).
Table 2. Multivariable regression analyseswith FGF21 (pg/mL) as
dependent variable and energy-adjusted protein intake
at baseline (g/day) as independent variable
a) p value 95% CI
Protein intake
(continuous
variable)
Model 1b) −3.42 0.006 −5.83, −1.02
Model 2c) −3.39 0.007 −5.86, −0.92
Quartiles of
protein
intake
Model 1b) −31.5 0.01 −56.5, −6.5
Model 2c) −30.8 0.02 −56.5, −5.0
CI: Confidence interval.
a)Parameter estimates.
b)Unadjusted.
c)Adjusted for body mass index (BMI) and total energy intake.
Figure 7. Circulating FGF21 levels correlate negatively with pro-
tein intake. Plasma FGF21 concentration divided into quartiles of
protein intake adjusted for the calorie intake of 78 participants
in the PREDIMED trial. Error bars represent the mean ± SEM.
*p<0,05 from first quartile; #p<0,05 from the second quartile.
this growth factor. The LFgf21KO mice revealed the
relevance of FGF21 in the response to an LPD, but also
in the metabolic and transcriptional pathways activated or
repressed by protein restriction.
Given the parallelism between the results of our study in
humans and those in mice, we postulate that dietary protein
content is crucial for the modulation of circulating FGF21
levels and thus for the activity of this hormone in target tissues
in mice and that it could also be in humans. We propose to
investigate a dietary intervention consisting of a reduction
in protein intake as a non-invasive approach to induce the
hepatic expression of FGF21. We also describe the molecular
mechanisms through which a LPD—via FGF21—could be
beneficial to restore lipid/glucose homeostasis.
Studies performed in humans provide contradictory re-
sults regarding the correlation between plasma levels of
FGF21, BMI, and insulin resistance [41–43]. Also, the FGF21-
resistant state described inmice [44] is not well established in
humans and the beneficial effects of FGF21 induction have
yet to be demonstrated in the latter.
Our findings provide new insight into the modulation of
dietary protein as a strategy to induce elevated serum concen-
trations of FGF21. Further studies will be needed to evaluate
the effects of an LPD / FGF21 induction on the metabolic
profile of obese and insulin-resistant subjects.
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SUMMARY 
 
Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic candidate for the 
treatment of obesity and metabolic disorders. Since FGF21 production is regulated by 
various nutritional factors, we analyze the impact of low protein intake on circulating levels of 
this growth hormone in mice and in a sub cohort of the PREDIMED (Prevención con Dieta 
Mediterránea) trial. We also describe the role of hepatic FGF21 in metabolic adaptation to a 
low-protein diet (LPD).  
 
RESULTS 
 
We fed control and liver-specific Fgf21 knockout (LFgf21KO) mice a LPD. This diet 
increased FGF21 production by inducing its overexpression in liver (Figure 1), and this 
correlated with the induction of the transcription factor ATF4 (Figure 2) and a body weight 
decrease without changes in food intake (Figure 3).  
Figure 1. FGF21 is induced by a LPD in liver, and this induction correlates positively 
with plasma concentration in mice. Plasma protein concentration of FGF21 was 
measured by ELISA (A). Fgf21 mRNA levels in liver (B) were measured by qRT-PCR. Error 
bars represent the mean ± SEM. ** p<0.01 ***p<0.001 versus Fgf21LoxP mice fed a CD 
(n=7–9/group).  
Figure 2. A LPD increases ATF4 protein 
levels in liver. ATF4 protein levels were 
determined by Western blot analysis using 
hepatic nuclear extracts obtained from 
Fgf21LoxP mice administered a CD or LPD (A). 
The experiment was normalized by actin protein 
levels as loading control and the intensity of the 
bands were quantified by densitometry with the 
Image J software (B). Error bars represent the 
mean ± SEM. **p<0.01 versus CD. (n=3/group). 
Figure 3. Hepatic FGF21 expression is required for the weight loss caused by LPD but 
does not affect food consumption. Body weight progression of mice fed a CD or LPD 
expressed as percentage of the initial weight, which was considered 100% (A). Total body 
weight change (g) after 7 days on a CD or LPD (B). Daily food intake (C). Error bars 
represent the mean ± SEM. ** p<0.01 versus Fgf21LoxP mice fed a CD, # p<0.05 versus 
LFgf21KO fed a CD; 0.07 represents p value versus LFgf21KO mice fed a CD (n=7–9/
group).  
The LPD also caused FGF21-dependent browning in subcutaneous white adipose tissue 
(scWAT), as indicated by an increase in the expression of uncoupling protein 1 (UCP1) 
(Figure 4).  
Figure 4. Hepatic FGF21 is required for inducing thermogenic gene expression during 
a LPD. Ucp1, Dio2, Pgc1a, Pparg, Prmd16 and Cidea expression was measured by qRT-
PCR in mouse scWAT. Error bars represent the mean ± SEM. * p<0.05 versus Fgf21LoxP 
mice fed a CD (n=7–9/group). 
In a subgroup of 78 individuals from the PREDIMED trial, we observed an inverse 
correlation between protein intake and circulating FGF21 levels (Figure 5).  
Figure 5. Circulating FGF21 levels correlate negatively with protein intake. Plasma 
FGF21 concentration divided into quartiles of protein intake adjusted for the calorie intake of 
78 participants in the PREDIMED trial. Error bars represent the mean ± SEM. * p<0,05 from 
1st quartile; # p<0,05 from the 2nd quartile.  
GRAPHIC ABSTRACT 
 
Our results reinforce the involvement of FGF21 in coordinating energy homeostasis under a 
range of nutritional conditions. Moreover, here we describe an approach to increase the 
endogenous production of FGF21, which if demonstrated functional in humans, could 
generate a treatment for obesity. 
 
